Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
38.2 /100
Rank 66 out of 131 Industries -
Advance/Decline
191/149
-
No. of Companies340
-
Avg. Market Cap14,067
-
Price to Earning Ratio5.12
-
Price to Earning Growth Ratio1.01
-
Price to Book Ratio22.98
-
Return on Equity12.27
-
Return on Capital Employed-
-
Return on Assets7.40
-
Dividend yield 1 year %0.71 %
-
Net Profit Growth Annual YoY %-66.45 %
-
Net Profit Growth Qtr YoY %-1012.84 %
-
Net Profit Growth Qtr QoQ %-284.81 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
415,002.0
|
234.9
|
L
 0.1%
H
232.9
237.4
|
L
 5.6%
H
215.4
237.4
|
L
 8.9%
H
209.0
237.4
|
L
 14.6%
H
190.8
237.4
|
L
 27.8%
H
181.7
244.8
|
L
 72.8%
H
131.0
244.8
|
L
 106.0%
H
105.6
244.8
|
L
 283.1%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
136.1
|
1.1
|
L
 -7.0%
H
1.1
1.2
|
L
 7%
H
1.0
1.2
|
L
 -68.4%
H
0.8
3.7
|
L
 -73.6%
H
0.8
4.8
|
L
 -60.1%
H
0.8
5.0
|
L
 -47.8%
H
0.4
6.0
|
L
 -95.7%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
5,509.5
|
17.3
|
L
 3.7%
H
16.8
17.4
|
L
 6.3%
H
15.7
17.4
|
L
 39.1%
H
12.5
17.4
|
L
 44.9%
H
11.7
17.4
|
L
 118.1%
H
7.7
17.4
|
L
 499.7%
H
2.3
17.4
|
L
 228.3%
H
1.2
17.4
|
L
 -43.1%
H
1.2
32.2
|
| Annovis Bio Inc |
|
72.3
|
1.7
|
L
 -2.3%
H
1.7
1.8
|
L
 -5.0%
H
1.7
1.9
|
L
 -23.8%
H
1.7
2.3
|
L
 -32%
H
1.5
2.8
|
L
 -35.6%
H
1.5
5.5
|
L
 -88.2%
H
1.1
22.5
|
L
 -97.8%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
1,863.6
|
5.0
|
L
 4.0%
H
4.8
5.1
|
L
 0.6%
H
4.6
5.1
|
L
 -8.8%
H
4.6
5.6
|
L
 -2.2%
H
4.6
6.3
|
L
 -18.2%
H
4.6
8.7
|
L
 -30.6%
H
4.0
11.5
|
L
 -82.8%
H
4.0
30.3
|
L
 -77.6%
H
4.0
34.8
|
| Bristol-Myers Squibb |
|
112,313.9
|
55
|
L
 -1.0%
H
54.8
56.6
|
L
 -1.7%
H
53.4
56.6
|
L
 -7.5%
H
53.4
59.8
|
L
 -3.5%
H
53.4
62.2
|
L
 17.2%
H
42.5
62.9
|
L
 -15.4%
H
39.4
65.4
|
L
 -15.7%
H
39.4
81.4
|
L
 -24.3%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
435.0
|
8.4
|
L
 5.2%
H
8.0
8.5
|
L
 8.8%
H
7.8
8.5
|
L
 -0.2%
H
7.6
9.4
|
L
 4.7%
H
7.5
9.7
|
L
 29.3%
H
5.6
14.1
|
L
 -9.5%
H
1.4
15.1
|
L
 -86.0%
H
1.4
68.0
|
L
 -70.9%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
102,349.6
|
51.1
|
L
 -1.9%
H
51.0
52.2
|
L
 -2.2%
H
50.4
52.8
|
L
 -0.6%
H
48.6
53.5
|
L
 -1.7%
H
48.6
59.6
|
L
 33.5%
H
35.5
61.7
|
L
 40.4%
H
31.7
61.7
|
L
 25.9%
H
28.5
61.7
|
L
 17.9%
H
28.5
61.7
|
| Johnson & Johnson |
|
580,139.3
|
241
|
L
 0.8%
H
238.8
243.0
|
L
 2.5%
H
227.5
243.0
|
L
 3.4%
H
220.8
243.0
|
L
 2.4%
H
220.4
247.2
|
L
 59.3%
H
150.7
251.7
|
L
 45.6%
H
140.7
251.7
|
L
 48.2%
H
140.7
251.7
|
L
 105.3%
H
109.2
251.7
|
| Eli Lilly |
|
996,307.0
|
1,117.3
|
L
 0.9%
H
1101.0
1135.1
|
L
 -0.5%
H
1079.2
1135.1
|
L
 4.9%
H
1052.2
1182.7
|
L
 22.7%
H
850.5
1182.7
|
L
 45.0%
H
623.8
1182.7
|
L
 143.5%
H
434.3
1182.7
|
L
 414.6%
H
220.2
1182.7
|
L
 1411.0%
H
64.2
1182.7
|
| Merck & Company |
|
297,860.8
|
120.6
|
L
 0.8%
H
119.5
121.8
|
L
 4.7%
H
111.6
121.8
|
L
 -1.5%
H
111.6
123.5
|
L
 4.3%
H
107.9
124
|
L
 50.5%
H
76.7
125.1
|
L
 5.2%
H
73.3
134.6
|
L
 59.6%
H
70.9
134.6
|
L
 119.1%
H
50.4
134.6
|
| Novo Nordisk (ADR) |
|
209,877.2
|
47.4
|
L
 0.0%
H
47.0
47.7
|
L
 8.9%
H
42.5
47.7
|
L
 5.5%
H
41
47.7
|
L
 28.8%
H
35.1
47.8
|
L
 -32%
H
35.1
71.8
|
L
 -40.4%
H
35.1
148.2
|
L
 16.1%
H
35.1
148.2
|
L
 77.6%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
292,167.0
|
153.1
|
L
 -0.2%
H
152.3
155.0
|
L
 1.5%
H
146.6
155.0
|
L
 0.7%
H
142.3
155.0
|
L
 3.4%
H
142.3
156.5
|
L
 30.3%
H
112.3
170.5
|
L
 52.1%
H
92.2
170.5
|
L
 65.7%
H
74.1
170.5
|
L
 114.7%
H
59.2
170.5
|
| Organon & Co. |
|
3,540.0
|
13.5
|
L
 0.2%
H
13.4
13.5
|
L
 0.5%
H
13.4
13.5
|
L
 0.4%
H
13.3
13.5
|
L
 121.4%
H
5.7
13.5
|
L
 37.6%
H
5.7
13.5
|
L
 -33.4%
H
5.7
24.1
|
L
 -54.3%
H
5.7
39.5
|
L
H
5.7
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,241.7
|
47.3
|
L
 2.8%
H
45.8
47.9
|
L
 -0.4%
H
45.2
48.0
|
L
 -1.4%
H
44.5
49.8
|
L
 -24.6%
H
42.6
63.2
|
L
 -43.9%
H
42.6
85.3
|
L
 -17.3%
H
42.6
90.0
|
L
 -9.3%
H
42.6
90.0
|
L
 -13.2%
H
26.3
90.0
|
| Pfizer |
|
137,014.6
|
24.0
|
L
 -2.8%
H
23.9
25.1
|
L
 -7.7%
H
23.9
26.3
|
L
 -7.2%
H
23.9
26.5
|
L
 -10.2%
H
23.9
28.7
|
L
 0.0%
H
23.1
28.7
|
L
 -37.2%
H
20.9
37.8
|
L
 -38.4%
H
20.9
61.7
|
L
 -26.6%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,350.5
|
9.8
|
L
 2.9%
H
9.5
9.8
|
L
 -8.5%
H
9.4
10.8
|
L
 -13.0%
H
9.4
12.0
|
L
 2.0%
H
9.3
12.6
|
L
 -63.1%
H
9.2
28.4
|
L
 -70.9%
H
9.2
40.3
|
L
 -78.8%
H
9.2
50.9
|
L
 -89.7%
H
9.2
99.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
12,207.5
|
14.7
|
L
 2.5%
H
14.3
14.7
|
L
 10.2%
H
13.1
14.7
|
L
 7.8%
H
13.0
14.7
|
L
 7.1%
H
12.2
14.7
|
L
 -4.3%
H
12.2
15.7
|
L
 20.2%
H
12.2
74.9
|
L
 2.7%
H
9.6
74.9
|
L
 52.7%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
49,671.2
|
15.7
|
L
 -0.8%
H
15.7
15.9
|
L
 0.4%
H
15.3
15.9
|
L
 -3.3%
H
14.8
16.3
|
L
 -12.0%
H
14.8
18.9
|
L
 6.8%
H
13.0
18.9
|
L
 -1.3%
H
12.6
18.9
|
L
 -5.8%
H
12.3
18.9
|
L
 -25.2%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
39,846.7
|
34.2
|
L
 3.0%
H
33.2
34.6
|
L
 4.0%
H
30.8
34.6
|
L
 0.4%
H
30.8
35.5
|
L
 18.9%
H
27.9
37.0
|
L
 101.7%
H
15.0
37.3
|
L
 349.1%
H
7.4
37.3
|
L
 235.5%
H
6.8
37.3
|
L
 -33.4%
H
6.1
56.4
|
| Zoetis (Class A) |
|
32,771.1
|
78.2
|
L
 1.7%
H
77.4
79.1
|
L
 -1.5%
H
75.6
80.0
|
L
 -3.9%
H
74.9
83.0
|
L
 -32.2%
H
72.4
123.3
|
L
 -50.3%
H
72.4
161.8
|
L
 -53.6%
H
72.4
201.9
|
L
 -58.0%
H
72.4
249.3
|
L
 63.2%
H
45.3
249.3
|
| Biohaven Ltd |
|
2,252.4
|
15.0
|
L
 1.2%
H
14.5
15.2
|
L
 23.7%
H
13.0
15.8
|
L
 58.3%
H
9.5
15.8
|
L
 71.2%
H
8.0
15.8
|
L
 3.5%
H
7.5
18.6
|
L
 -35.5%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Abeona Therapeutics Inc |
|
320.3
|
5.6
|
L
 -1.8%
H
5.6
5.8
|
L
 -0.5%
H
5.6
5.9
|
L
 3.3%
H
5.2
5.9
|
L
 27.2%
H
4.2
6.1
|
L
 -3.3%
H
4
7.5
|
L
 13.1%
H
2.9
9.0
|
L
 -86.1%
H
2.2
43.8
|
L
 -91.7%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
4,951.0
|
82.1
|
L
 -1.6%
H
80.4
85.7
|
L
 21.2%
H
67.9
88.8
|
L
 35.4%
H
53.6
88.8
|
L
 97.5%
H
39.1
91
|
L
 653.1%
H
10.8
91
|
L
 235.3%
H
2.2
91
|
L
 93.8%
H
2.2
91
|
L
 -87.4%
H
2.2
725.8
|
| Acumen Pharma Inc |
|
166.8
|
2.3
|
L
 -4.2%
H
2.3
2.5
|
L
 0.9%
H
2.2
2.5
|
L
 -8.0%
H
2.1
2.7
|
L
 -14.8%
H
2.1
3.0
|
L
 87.8%
H
1.1
3.6
|
L
 -57.4%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
881.0
|
4.5
|
L
 0.2%
H
4.4
4.5
|
L
 1.6%
H
4.4
4.8
|
L
 2.5%
H
4.1
4.8
|
L
 0.9%
H
4.0
4.8
|
L
 30.8%
H
3.0
5.1
|
L
 85.1%
H
1.7
5.1
|
L
 39.8%
H
1.7
6.5
|
L
 26.0%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
34.6
|
1.3
|
L
 1.5%
H
1.3
1.4
|
L
 3.1%
H
1.3
1.4
|
L
 16.7%
H
1.1
1.5
|
L
 8.1%
H
0.9
1.8
|
L
 -32.1%
H
0.9
5.5
|
L
 -74.9%
H
0.4
6.9
|
L
 -97.3%
H
0.4
116.9
|
L
 -99.6%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,000.1
|
23.4
|
L
 3.4%
H
22.7
23.8
|
L
 11.6%
H
20.9
23.8
|
L
 10.7%
H
20.8
23.8
|
L
 11.3%
H
20.3
23.8
|
L
 3.9%
H
19.7
28.4
|
L
 -4.7%
H
13.4
33.9
|
L
 -4.7%
H
12.2
33.9
|
L
 -30.3%
H
12.2
58.7
|
| Adicet Bio Inc |
|
77.1
|
8.3
|
L
 1.2%
H
8.1
8.4
|
L
 6.3%
H
7.8
8.4
|
L
 -0.6%
H
7.0
9.5
|
L
 23.9%
H
6.0
9.5
|
L
 -18.8%
H
6.0
17.4
|
L
 -89.1%
H
6.0
77.0
|
L
 -94.4%
H
6.0
349.9
|
L
H
6.0
349.9
|
| Achieve Life Sciences Inc |
|
544.1
|
5.3
|
L
 5.8%
H
4.9
5.4
|
L
 -4.5%
H
4.8
5.6
|
L
 13.0%
H
4.5
6.2
|
L
 30.9%
H
2.6
6.2
|
L
 38.0%
H
2
6.2
|
L
 -10.3%
H
1.8
6.2
|
L
 -36.8%
H
1.8
10.3
|
L
 -99.8%
H
1.8
2332
|
| AC Immune SA |
|
258.5
|
2.5
|
L
 3.7%
H
2.4
2.6
|
L
 7.2%
H
2.3
2.6
|
L
 -10.3%
H
2.1
3.0
|
L
 -11.8%
H
2.1
3.5
|
L
 38.8%
H
1.7
4
|
L
 33.7%
H
1.4
5.1
|
L
 -68.8%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
669.0
|
4.8
|
L
 -2.6%
H
4.7
5
|
L
 10.4%
H
4.3
5.1
|
L
 6.0%
H
4.1
5.1
|
L
 33.8%
H
3.2
5.2
|
L
 244.6%
H
1.4
5.2
|
L
 -53.3%
H
0.6
11.1
|
L
 -72.2%
H
0.6
20.0
|
L
 -73.7%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
69.3
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 8.7%
H
1.5
1.7
|
L
 -7.4%
H
1.4
1.8
|
L
 1.3%
H
1.3
2.2
|
L
 37.3%
H
1.2
3.6
|
L
 -88.1%
H
1.1
13.9
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
18.0
|
1.1
|
L
 1.0%
H
1.1
1.1
|
L
 15.2%
H
0.9
1.1
|
L
 29.3%
H
0.8
1.1
|
L
 32.5%
H
0.7
1.1
|
L
 140.9%
H
0.4
1.6
|
L
 -3.6%
H
0.4
1.6
|
L
 -96.1%
H
0.4
31
|
L
 -98.1%
H
0.4
115
|
| Grace Therapeutics Inc |
|
37.9
|
2.3
|
L
 -2.5%
H
2.3
2.5
|
L
 5.0%
H
2.2
2.5
|
L
 5.9%
H
2.1
2.7
|
L
 -47.4%
H
1.8
5.2
|
L
 -20.5%
H
1.8
5.2
|
L
 -30.7%
H
1.7
5.2
|
L
 -91.9%
H
1.7
30.7
|
L
 -96.7%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
6.3
|
1.5
|
L
 3.5%
H
1.4
1.5
|
L
 -4.6%
H
1.4
1.6
|
L
 -25.4%
H
1.4
2.1
|
L
 -67.5%
H
1.4
5.4
|
L
 -87.8%
H
1.3
12.6
|
L
 -97.1%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
5.4
|
2.5
|
L
 -2.8%
H
2.3
2.6
|
L
 -2.4%
H
2.3
2.9
|
L
 19.2%
H
2.0
5.2
|
L
 34.8%
H
1.3
5.2
|
L
 -62.3%
H
1.3
18.9
|
L
 -98.2%
H
1.3
350
|
L
 -99.9%
H
1.3
3175
|
L
H
1.3
5900
|
| Agios Pharma Inc |
|
2,157.6
|
36.3
|
L
 1.9%
H
35.3
36.9
|
L
 13.9%
H
31.8
36.9
|
L
 28.9%
H
26.4
36.9
|
L
 29.1%
H
24.3
36.9
|
L
 8.8%
H
22.2
46
|
L
 35.4%
H
19.8
62.6
|
L
 -35.7%
H
16.8
62.6
|
L
 -25.2%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
284.4
|
1.1
|
L
 -3.6%
H
1.1
1.1
|
L
 8.2%
H
1.0
1.1
|
L
 3.9%
H
0.8
1.1
|
L
 -24.3%
H
0.8
1.6
|
L
 -70.9%
H
0.8
4.1
|
L
 3.9%
H
0.8
4.1
|
L
 -73.2%
H
0.2
4.3
|
L
 -86.4%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
34.5
|
5.6
|
L
 -1.2%
H
5.4
5.8
|
L
 11.8%
H
5.1
5.9
|
L
 -3.1%
H
4.8
6.0
|
L
 -18.8%
H
4.8
9.0
|
L
 -22.3%
H
4.8
13.7
|
L
 -76.9%
H
3.8
46.3
|
L
 -99.1%
H
3.8
709.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
8,408.8
|
50.5
|
L
 5.0%
H
48.9
51.7
|
L
 14.4%
H
44.0
51.7
|
L
 37.1%
H
36.5
51.7
|
L
 82.1%
H
27.3
51.7
|
L
 72.4%
H
25.2
51.7
|
L
 51.3%
H
22.0
51.7
|
L
 108.7%
H
21.2
51.7
|
L
 15.3%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
20.7
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -9.1%
H
1.3
1.5
|
L
 -26.6%
H
1.3
1.8
|
L
 14.0%
H
1.0
1.8
|
L
 44.4%
H
0.8
2.1
|
L
 -99.1%
H
0.1
269.8
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
39,260.7
|
294.1
|
L
 2.0%
H
288.9
303.5
|
L
 4.3%
H
273.1
303.5
|
L
 -1.1%
H
273.1
310.5
|
L
 -4.1%
H
273.1
343.4
|
L
 -6.1%
H
273.1
495.6
|
L
 52.6%
H
142.0
495.6
|
L
 68.4%
H
117.6
495.6
|
L
 416.3%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
86.4
|
1.0
|
L
 4.1%
H
1.0
1.0
|
L
 7.5%
H
0.9
1.0
|
L
 -1.9%
H
0.9
1.2
|
L
 -15.1%
H
0.9
2.1
|
L
 -32.7%
H
0.9
2.2
|
L
 -41.6%
H
0.9
7.4
|
L
 -96.0%
H
0.9
28
|
L
H
0.9
309.6
|
| Alzamend Neuro Inc |
|
5.2
|
1.4
|
L
H
1.3
1.4
|
L
 7.0%
H
1.2
1.4
|
L
 21.2%
H
1.1
1.4
|
L
 -26.3%
H
0.8
1.9
|
L
 -53.6%
H
0.8
3.6
|
L
 -99.8%
H
0.8
810
|
L
 -100.0%
H
0.8
16389
|
L
H
0.8
45292.5
|
| Amylyx Pharma Inc |
|
1,890.2
|
17
|
L
 3.9%
H
16.1
17.2
|
L
 13.0%
H
15.0
17.2
|
L
 25.2%
H
12.6
17.2
|
L
 25.7%
H
12.4
18.6
|
L
 238.7%
H
5.3
18.6
|
L
 -26.3%
H
1.6
25.5
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
926.8
|
21.0
|
L
 7.6%
H
19.8
21.1
|
L
 5.3%
H
18.2
21.1
|
L
 14.2%
H
17.7
21.1
|
L
 9.3%
H
16.6
24.3
|
L
 -14.8%
H
16.6
31.3
|
L
 -63.2%
H
16.6
67.7
|
L
 3.5%
H
16.6
67.7
|
L
 30.2%
H
12.1
67.7
|
| Annexon Inc |
|
868.4
|
5.3
|
L
 0.4%
H
5.3
5.6
|
L
 17.3%
H
4.5
5.6
|
L
 -0.2%
H
4.5
5.9
|
L
 -1.3%
H
4.5
6.6
|
L
 122.7%
H
1.9
7.2
|
L
 52.3%
H
1.3
8.4
|
L
 -77.8%
H
1.3
24.9
|
L
H
1.3
38.0
|
| Apollomics Inc (Class A) |
|
45.0
|
20.5
|
L
 2.0%
H
19
21.4
|
L
 41.5%
H
12.9
22.9
|
L
 45.6%
H
12.9
22.9
|
L
 15.2%
H
12.6
22.9
|
L
 283.9%
H
3.7
42.1
|
L
 -96.0%
H
0.1
620
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Aptorum Grp Ltd (Class A) |
|
6.6
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -3.6%
H
0.8
0.9
|
L
 -4.7%
H
0.8
1.4
|
L
 -33.1%
H
0.8
1.4
|
L
 -16.5%
H
0.7
4.5
|
L
 -71.1%
H
0.5
17.5
|
L
 -97.4%
H
0.5
33.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
10.0
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 11.0%
H
0.7
0.9
|
L
 -14.7%
H
0.7
1.0
|
L
 19.1%
H
0.6
1.1
|
L
 -49.4%
H
0.6
2.2
|
L
 -74.3%
H
0.6
8.9
|
L
 -99.2%
H
0.6
117.8
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
626.0
|
5.0
|
L
 -0.8%
H
4.9
5.2
|
L
 17.1%
H
4.2
5.2
|
L
 21.1%
H
3.9
5.2
|
L
 27.0%
H
3.8
5.2
|
L
 51.7%
H
2.9
7.6
|
L
 172.7%
H
1.3
7.6
|
L
 12.4%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
199.2
|
7.0
|
L
 -1.0%
H
7.0
7.4
|
L
 -1.8%
H
7.0
7.9
|
L
 -0.3%
H
6.7
8.2
|
L
 2.0%
H
6.6
9.6
|
L
 -44.0%
H
5.9
24.2
|
L
 -70.7%
H
5.9
45
|
L
 -79.4%
H
5.9
65
|
L
 -75.6%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,529.1
|
6.2
|
L
 0.2%
H
6.1
6.4
|
L
 9.2%
H
5.7
6.5
|
L
 1.3%
H
5.3
6.5
|
L
 16.6%
H
5.1
7.4
|
L
 70.5%
H
3.6
8.4
|
L
 71.9%
H
3.2
10.1
|
L
 -15.9%
H
0.5
10.1
|
L
 -25.2%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,423.5
|
27.4
|
L
 4.2%
H
26.5
28.1
|
L
 6.6%
H
25.4
28.1
|
L
 31.2%
H
20.5
28.1
|
L
 22.8%
H
19.3
28.1
|
L
 90.1%
H
13.1
31.8
|
L
 211.7%
H
1.8
31.8
|
L
 1.8%
H
1.8
31.8
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
4.0
|
1.2
|
L
 -7.9%
H
1.2
1.3
|
L
 -10.1%
H
1.2
1.3
|
L
 -2.5%
H
1.2
1.9
|
L
 -84.9%
H
1.2
19.9
|
L
 -93.4%
H
1.2
85.8
|
L
 -96.7%
H
1.2
85.8
|
L
 -99.6%
H
1.2
356.4
|
L
H
1.2
46656
|
| Assembly Biosciences Inc |
|
507.7
|
25.6
|
L
 -4.4%
H
25.3
28.0
|
L
 9.8%
H
23.2
28.0
|
L
 -9.6%
H
21.8
29.1
|
L
 -10.4%
H
21.8
32.5
|
L
 49.8%
H
16.8
39.7
|
L
 95.9%
H
7.7
39.7
|
L
 -46.4%
H
7.7
50.0
|
L
 -62.3%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
888.9
|
7.1
|
L
 -0.3%
H
6.7
7.3
|
L
 9.6%
H
6.5
7.6
|
L
 27.2%
H
5.7
8.5
|
L
 46.2%
H
3.9
8.5
|
L
 -3.4%
H
3.9
14.5
|
L
 1370.8%
H
0.4
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| ATAI Life Sciences N.V. |
|
1,535.3
|
4.2
|
L
 1.7%
H
4.1
4.3
|
L
 0.7%
H
4.0
4.3
|
L
 -3.5%
H
3.7
5
|
L
 23.0%
H
3.3
5.5
|
L
 106.4%
H
2
6.8
|
L
 169.0%
H
1.0
6.8
|
L
 -77.3%
H
1.0
20.5
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
73.7
|
5.1
|
L
 0.8%
H
4.8
5.2
|
L
 -4.5%
H
4.8
5.5
|
L
 11.7%
H
4.0
5.8
|
L
 73.6%
H
1.8
5.9
|
L
 -41.4%
H
1.8
174.6
|
L
 -97.7%
H
1.8
226.1
|
L
 -100.0%
H
1.8
44612
|
L
H
1.8
49571
|
| Atossa Therapeutics Inc |
|
17.5
|
1.8
|
L
 -7.9%
H
1.8
1.9
|
L
 -21.2%
H
1.8
2.2
|
L
 -64.7%
H
1.8
5.3
|
L
 -68.8%
H
1.8
6.3
|
L
 -85.4%
H
1.8
19.4
|
L
 -86.9%
H
1.8
34.7
|
L
 -98.4%
H
1.8
147
|
L
 -99.8%
H
1.8
891
|
| Atara Biotherapeutics Inc |
|
95.1
|
10.6
|
L
 -5.5%
H
10.5
11.1
|
L
 9.7%
H
9.4
11.6
|
L
 7.7%
H
9.2
11.6
|
L
 118.0%
H
4.3
12.5
|
L
 33.9%
H
3.9
19.1
|
L
 -76.0%
H
0.4
63.4
|
L
 -97.3%
H
0.4
501
|
L
 -98.1%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
358.5
|
4.5
|
L
H
4.4
4.6
|
L
 5.2%
H
4.2
4.6
|
L
 1.4%
H
4.2
4.8
|
L
 -19.6%
H
4.0
6.3
|
L
 34.9%
H
2.8
6.5
|
L
 13.1%
H
2.5
6.5
|
L
 -80.7%
H
2.5
46.9
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
954.6
|
18.2
|
L
 1.9%
H
17.8
18.4
|
L
 26.7%
H
14.3
18.5
|
L
 11.1%
H
12.5
18.5
|
L
 34.5%
H
12.5
24.3
|
L
 279.1%
H
4.5
24.3
|
L
 310.9%
H
0.0
34.5
|
L
 -58.5%
H
0.0
43.8
|
L
 -34.2%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
23.5
|
2.2
|
L
 -2.7%
H
2.2
2.3
|
L
 5.3%
H
2.1
2.3
|
L
H
2.0
2.4
|
L
 -16.7%
H
2.0
2.8
|
L
 10.6%
H
1.7
3.1
|
L
 31.1%
H
1.0
3.5
|
L
 -98.1%
H
1.0
114
|
L
 -100.0%
H
1.0
400000
|
| Adagene Inc (ADR) |
|
280.8
|
4.3
|
L
 6.8%
H
3.5
4.3
|
L
 21.1%
H
3.3
4.3
|
L
 13.3%
H
3.2
4.3
|
L
 8.4%
H
3.1
4.8
|
L
 123.7%
H
1.3
4.8
|
L
 214.8%
H
1.1
4.8
|
L
 -69.6%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.6
|
6
|
L
 -7.0%
H
5.7
6.3
|
L
 -3.4%
H
5.6
7.1
|
L
 -12.2%
H
5.6
7.3
|
L
 -3.5%
H
5.4
7.6
|
L
 -26.9%
H
5.4
12.1
|
L
 -53.8%
H
5
27.9
|
L
 -97.0%
H
5
218
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
344.1
|
16.4
|
L
 2.8%
H
15.8
16.7
|
L
 8.2%
H
15.2
17.3
|
L
 13.7%
H
13.6
17.3
|
L
 12.4%
H
13.0
17.3
|
L
 30.2%
H
13.0
20.9
|
L
 1339.5%
H
0.4
20.9
|
L
 261.5%
H
0.4
20.9
|
L
 681.4%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
14,612.2
|
238.0
|
L
 -0.2%
H
237.3
241.8
|
L
 3.0%
H
222.8
241.8
|
L
 -3.7%
H
203.8
245.2
|
L
 9.2%
H
203.8
250.7
|
L
 35.4%
H
160.9
250.7
|
L
 169.9%
H
85.1
250.7
|
L
 71.5%
H
61.6
250.7
|
L
 1617.2%
H
12.3
250.7
|
| Alterity Therapeutics Ltd (ADR) |
|
91.7
|
5.1
|
L
 2.0%
H
5.1
5.3
|
L
 8.8%
H
4.8
5.3
|
L
 22.2%
H
3.9
5.3
|
L
 53.3%
H
3.1
5.3
|
L
 15.8%
H
2.7
7
|
L
 79.4%
H
1
7
|
L
 -61.4%
H
1
27.5
|
L
 -89.4%
H
1
66.9
|
| Astrazeneca plc |
|
567,465.8
|
183.0
|
L
 1.1%
H
182.2
184.6
|
L
 2.4%
H
173.7
184.6
|
L
 -2.1%
H
173.7
188.7
|
L
 -0.6%
H
173.7
207.3
|
L
 -2.9%
H
173.7
212.7
|
L
 -2.9%
H
173.7
212.7
|
L
 -2.9%
H
173.7
212.7
|
L
 -2.9%
H
173.7
212.7
|
| Biofrontera Inc |
|
12.8
|
1
|
L
 -2.9%
H
1.0
1.1
|
L
 4.2%
H
1.0
1.2
|
L
 23.5%
H
0.8
1.2
|
L
 17.7%
H
0.7
1.2
|
L
 58.7%
H
0.6
1.2
|
L
 -89.5%
H
0.5
13.0
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biomea Fusion Inc |
|
90.4
|
1.3
|
L
 1.6%
H
1.2
1.3
|
L
 7.8%
H
1.2
1.3
|
L
 -12.0%
H
1.1
1.5
|
L
 11.6%
H
1.1
2.2
|
L
 -26.0%
H
0.9
3.0
|
L
 -95.9%
H
0.9
33
|
L
 -92.5%
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
8.1
|
4.2
|
L
 -0.9%
H
4.2
4.3
|
L
 -2.1%
H
3.8
4.7
|
L
 -14.8%
H
3.8
5.7
|
L
 -3.7%
H
3.8
5.7
|
L
 -24.6%
H
3.8
7.2
|
L
 -84.8%
H
3.8
31.2
|
L
 -98.6%
H
3.8
385.7
|
L
H
3.8
861.4
|
| Blue Water Biotech Inc |
|
17.8
|
1
|
L
 -6.5%
H
1.0
1.1
|
L
 -7.4%
H
0.9
1.1
|
L
 -19.4%
H
0.9
1.4
|
L
 66.7%
H
0.1
6.7
|
L
 -75.2%
H
0.1
6.7
|
L
 -21.9%
H
0.1
6.7
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
67.4
|
1.6
|
L
 1.9%
H
1.6
1.7
|
L
 2.5%
H
1.6
1.7
|
L
 4.5%
H
1.4
1.8
|
L
 -0.6%
H
1.2
1.8
|
L
 -40.2%
H
1.2
2.9
|
L
 35.5%
H
0.7
4
|
L
 -85.3%
H
0.5
33
|
L
H
0.5
48.5
|
| Biodexa Pharma PLC (ADR) |
|
1.9
|
2.6
|
L
 -1.9%
H
2.6
2.8
|
L
 -12.4%
H
2.5
3.2
|
L
 -20.4%
H
2.5
3.8
|
L
 -23.7%
H
2.5
6.8
|
L
 -94.3%
H
2.5
66.5
|
L
 -100.0%
H
2.5
304375
|
L
 -100.0%
H
2.5
121450000
|
L
 -100.0%
H
2.5
10000000000
|
| BeiGene Ltd (ADR) |
|
29,520.5
|
277.1
|
L
 0.4%
H
275.8
282.9
|
L
 5%
H
259.1
282.9
|
L
 -10.7%
H
254.0
312.0
|
L
 0.9%
H
254.0
328.4
|
L
 7.6%
H
239.3
385.2
|
L
 54.6%
H
127.0
385.2
|
L
 -19.0%
H
118.2
426.6
|
L
 801.5%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
14.7
|
3.4
|
L
 3.4%
H
3.1
3.5
|
L
 10.5%
H
3.0
3.5
|
L
 10.1%
H
3.0
4.0
|
L
 45.3%
H
2.2
4.0
|
L
 -15.8%
H
2.2
5.1
|
L
 -94.8%
H
0.1
101.2
|
L
 -96.9%
H
0.1
144.8
|
L
 -99.3%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,043.6
|
150.8
|
L
 3.9%
H
144.5
152.7
|
L
 9.1%
H
136.2
152.7
|
L
 9.8%
H
130
152.7
|
L
 -0.2%
H
130
183.7
|
L
 145.2%
H
56.1
200
|
L
 1248.6%
H
11.5
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
24.3
|
4.5
|
L
 3.0%
H
4.4
4.5
|
L
 4.9%
H
4.0
4.6
|
L
 -18.1%
H
4.0
5.5
|
L
 -2.6%
H
3.8
5.5
|
L
 -25.8%
H
3.6
21.4
|
L
 118.0%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
1,709.0
|
29.5
|
L
 -0.3%
H
29.2
30.0
|
L
 13.3%
H
27.0
30.2
|
L
 2.2%
H
24.7
30.5
|
L
 -2.0%
H
24.7
36.8
|
L
 284.2%
H
4.3
40.4
|
L
 484.4%
H
2.7
40.4
|
L
 465.3%
H
2.6
40.4
|
L
 -32.6%
H
0.9
47.9
|
| Cullinan Oncology Inc |
|
1,084.7
|
17.7
|
L
 -0.6%
H
17.6
18.8
|
L
 30.3%
H
13.6
18.8
|
L
 27.5%
H
11.7
18.8
|
L
 37.5%
H
11.7
18.8
|
L
 132.9%
H
5.7
18.8
|
L
 42.1%
H
5.7
30.2
|
L
 -30.5%
H
5.7
30.3
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
234.5
|
1.5
|
L
 4.1%
H
1.5
1.6
|
L
 10.1%
H
1.4
1.6
|
L
 -5.6%
H
1.3
1.7
|
L
 -7.3%
H
1.3
2.1
|
L
 108.2%
H
0.7
2.6
|
L
 -61.9%
H
0.7
5.5
|
L
 -89.6%
H
0.7
19.3
|
L
 -90.8%
H
0.7
32.0
|
| Cingulate Inc |
|
64.8
|
4.8
|
L
 -0.4%
H
4.7
5.0
|
L
 1.5%
H
4.7
5.3
|
L
 7.6%
H
3.2
5.3
|
L
 -30.6%
H
3.2
7.0
|
L
 19.1%
H
3.2
11.9
|
L
 422.8%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
73.3
|
5.7
|
L
 -0.5%
H
5.6
5.9
|
L
 -1.9%
H
5.6
6.5
|
L
 -14.3%
H
5.3
6.8
|
L
 1.2%
H
4.5
8.7
|
L
 40%
H
3.3
13.5
|
L
 -64.1%
H
2.3
19
|
L
 -97.4%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
19.9
|
2.5
|
L
 -0.4%
H
2.5
2.6
|
L
 1.6%
H
2.4
2.9
|
L
 -22.2%
H
2.2
3.3
|
L
 -20.2%
H
2.2
4.7
|
L
 -72.1%
H
2.2
10.2
|
L
 -95.5%
H
2.2
133.5
|
L
 -99.3%
H
2.2
396
|
L
 -100.0%
H
2.2
11070
|
| Clearmind Medicine Inc |
|
4.0
|
2.7
|
L
 -9.8%
H
2.6
3.0
|
L
 -14.7%
H
2.6
3.4
|
L
 18.6%
H
2.3
4.7
|
L
 -60.1%
H
2.1
15.2
|
L
 -99.3%
H
2.1
524
|
L
 -100.0%
H
2.1
6840
|
L
 -100.0%
H
2.1
7884000
|
L
H
2.1
7884000
|
| Compass Therapeutics Inc |
|
363.8
|
2.0
|
L
 -1.9%
H
2.0
2.1
|
L
 2.5%
H
2.0
2.1
|
L
 -2.4%
H
1.9
2.5
|
L
 -59.9%
H
1.6
6.8
|
L
 -20.5%
H
1.6
6.9
|
L
 -35.9%
H
0.8
6.9
|
L
 -59.6%
H
0.8
6.9
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
6.1
|
4.2
|
L
 -2.8%
H
4.0
4.3
|
L
 -9.9%
H
4.0
4.7
|
L
 -23.1%
H
4.0
5.6
|
L
 65.5%
H
1.9
10.5
|
L
 -54.2%
H
1.9
12.4
|
L
 -100.0%
H
1.9
4125000
|
L
 -100.0%
H
1.9
120600000
|
L
H
1.9
256050000
|
| Context Therapeutics Inc |
|
53.3
|
0.6
|
L
 -10.8%
H
0.6
0.7
|
L
 -10.8%
H
0.6
0.7
|
L
 -77.7%
H
0.6
3.1
|
L
 -80.8%
H
0.6
3.3
|
L
 3.6%
H
0.6
3.6
|
L
 -56.7%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
14.5
|
1.1
|
L
 -0.9%
H
1.0
1.1
|
L
 10.5%
H
0.9
1.1
|
L
 -8.7%
H
0.9
1.3
|
L
 -2.8%
H
0.9
2.0
|
L
 -33.1%
H
0.9
2.7
|
L
 -56.3%
H
0.9
3.3
|
L
 -93.5%
H
0.9
17.9
|
L
 -99.4%
H
0.9
205.2
|
| Collegium pharma Inc |
|
1,154.0
|
35.6
|
L
 2.8%
H
34.9
36.1
|
L
 2.7%
H
31.7
36.1
|
L
 4.4%
H
30.1
36.1
|
L
 2.4%
H
30.1
40.5
|
L
 19.1%
H
29.2
50.8
|
L
 56.5%
H
20.8
50.8
|
L
 50.4%
H
14.0
50.8
|
L
 159.7%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
8,755.6
|
81.6
|
L
 2.1%
H
80.0
81.9
|
L
 -2.6%
H
77.4
85.4
|
L
 35.4%
H
59.0
85.4
|
L
 142.5%
H
33
85.4
|
L
 9.8%
H
28.7
91
|
L
 273.1%
H
20.8
117.3
|
L
 266.4%
H
15.8
117.3
|
L
 1391.0%
H
5.0
117.3
|
| Cosmos Health Inc |
|
13.0
|
0.2
|
L
H
0.2
0.2
|
L
 -16%
H
0.2
0.3
|
L
 -16%
H
0.2
0.3
|
L
 -38.2%
H
0.2
0.5
|
L
 -50%
H
0.2
1.3
|
L
 -93.5%
H
0.2
3.4
|
L
 -99.8%
H
0.2
155.3
|
L
 -99.8%
H
0.2
312.5
|
| Cumberland Pharma Inc |
|
90.6
|
6.1
|
L
 3.8%
H
5.8
6.1
|
L
 6.7%
H
5.5
6.1
|
L
 3.1%
H
5.4
6.6
|
L
 98.4%
H
2.9
6.6
|
L
 53.9%
H
1.9
6.6
|
L
 295.4%
H
1.0
7.3
|
L
 97.1%
H
1.0
7.5
|
L
 34.1%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
3,846.4
|
31.4
|
L
 0.1%
H
31.4
31.4
|
L
 0.2%
H
31.4
31.4
|
L
 0.5%
H
31.2
31.4
|
L
 34.7%
H
22.9
32.6
|
L
 42.0%
H
19.1
32.6
|
L
 138.9%
H
11.6
32.6
|
L
 442.7%
H
4.8
32.6
|
L
 3470.5%
H
0.7
32.6
|
| Corbus Pharma Holdings Inc |
|
151.6
|
8.2
|
L
 -3.3%
H
8.2
8.7
|
L
 3.8%
H
7.9
8.7
|
L
 -27.9%
H
7.1
10
|
L
 -3.0%
H
7.1
12.9
|
L
 3.7%
H
6.7
20.6
|
L
 -6.9%
H
3.0
61.9
|
L
 -86.3%
H
2.1
62.7
|
L
 -90.9%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
3,814.8
|
36.2
|
L
 0.8%
H
36
37.7
|
L
 3.4%
H
34.8
37.7
|
L
 -1.7%
H
32.3
37.7
|
L
 4.2%
H
32.3
43.6
|
L
 21.0%
H
25.8
58.0
|
L
 95.5%
H
15.8
62.5
|
L
 78.2%
H
15.2
62.5
|
L
H
10.6
62.5
|
| Corvus Pharma Inc |
|
1,089.0
|
13.0
|
L
 2.5%
H
12.5
13.2
|
L
 10.3%
H
11.7
13.2
|
L
 2.7%
H
10.8
14
|
L
 -5.8%
H
10.8
19.7
|
L
 247.2%
H
3.7
27.0
|
L
 491.3%
H
1.1
27.0
|
L
 377.9%
H
0.6
27.0
|
L
 -3.8%
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
722.8
|
3.3
|
L
 5.4%
H
3.1
3.4
|
L
 13.3%
H
2.9
3.4
|
L
 -11.7%
H
2.8
3.9
|
L
 -25.6%
H
2.8
5.1
|
L
 53.7%
H
1.7
8.2
|
L
 115.6%
H
0.4
8.2
|
L
 -50.3%
H
0.4
8.2
|
L
 -65.6%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
3.5
|
0.6
|
L
 -4.5%
H
0.6
0.7
|
L
 -22.0%
H
0.6
0.8
|
L
 -34.0%
H
0.6
2.8
|
L
 -37.9%
H
0.6
2.8
|
L
 -86.9%
H
0.6
19.9
|
L
 -100.0%
H
0.6
3168
|
L
 -100.0%
H
0.6
23904
|
L
 -100.0%
H
0.6
784800
|
| Cyclerion Therapeutics Inc |
|
13.6
|
3.1
|
L
 -4.0%
H
3.1
3.3
|
L
 -1.3%
H
3.0
3.4
|
L
 -1.3%
H
3.0
3.4
|
L
 97.5%
H
1.4
8.5
|
L
 9.0%
H
1.0
8.5
|
L
 -27.8%
H
1.0
8.5
|
L
 -95.8%
H
1.0
84.6
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
11,024.6
|
81.2
|
L
 1.5%
H
79.1
82.8
|
L
 8.0%
H
75.8
82.8
|
L
 5.5%
H
66.6
82.8
|
L
 33.2%
H
58.6
82.8
|
L
 148.8%
H
32.2
82.8
|
L
 130.6%
H
26.0
110
|
L
 264.0%
H
17.7
110
|
L
 803.2%
H
5.8
110
|
| Cellectis (ADR) |
|
280.7
|
2.8
|
L
 -3.8%
H
2.7
2.9
|
L
 -8.5%
H
2.7
3.2
|
L
 -20.3%
H
2.7
3.8
|
L
 -18.4%
H
2.7
4.6
|
L
 93.8%
H
1.4
5.5
|
L
 52.5%
H
1.0
5.5
|
L
 -81.1%
H
1.0
16.5
|
L
 -90.3%
H
1.0
38.9
|
| Centessa Pharma PLC (ADR) |
|
6,266.6
|
40.5
|
L
 0.8%
H
40
40.6
|
L
 1.9%
H
39.7
40.6
|
L
 1.9%
H
39.6
40.6
|
L
 56.1%
H
25.2
40.6
|
L
 211.5%
H
12.7
40.6
|
L
 513.6%
H
5.2
40.6
|
L
 70.2%
H
2.9
40.6
|
L
H
2.9
40.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
118.1
|
2.1
|
L
 1.4%
H
2.0
2.2
|
L
 6.5%
H
1.9
2.2
|
L
 -9.8%
H
1.9
2.7
|
L
 -28.1%
H
1.9
3.8
|
L
 116.3%
H
0.9
3.8
|
L
 73.8%
H
0.5
3.8
|
L
 -88.5%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
31.2
|
2.1
|
L
 0.5%
H
2
2.1
|
L
 -1.4%
H
2
2.2
|
L
 -12.2%
H
1.9
2.5
|
L
 51.8%
H
1.4
3.8
|
L
 -18.8%
H
1.3
9.2
|
L
 -81.8%
H
0.3
11.6
|
L
 -88.1%
H
0.3
30.1
|
L
 -99.2%
H
0.3
429.6
|
| Journey Medical Corp |
|
188.6
|
6.9
|
L
 2.2%
H
6.7
7.2
|
L
 12.1%
H
5.8
7.2
|
L
 14.9%
H
5.8
7.2
|
L
 -0.7%
H
4.3
7.2
|
L
 7.4%
H
4.3
9.6
|
L
 276.4%
H
1.5
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
3.3
|
L
 -12.4%
H
3.0
3.7
|
L
 -27.9%
H
3.0
7.8
|
L
 6.5%
H
2.1
7.8
|
L
 -18.9%
H
2.1
7.8
|
L
 -50%
H
2.1
13.1
|
L
 -38.5%
H
2.1
14.4
|
L
 -94.7%
H
2.1
64.1
|
L
 -100.0%
H
2.1
17437.5
|
| DiaMedica Therapeutics Inc |
|
342.7
|
6.4
|
L
 1.3%
H
6.3
6.7
|
L
 11.8%
H
5.6
6.7
|
L
 7.6%
H
5.2
6.7
|
L
 -12.8%
H
5.2
7.5
|
L
 74.3%
H
3.5
10.4
|
L
 49.6%
H
1.9
10.4
|
L
 -12.0%
H
1.1
10.4
|
L
 38.6%
H
1.1
13.8
|
| Dermata Therapeutics Inc |
|
4.9
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 1.7%
H
1.2
1.4
|
L
 -4.0%
H
1.2
1.4
|
L
 -22.9%
H
1.1
1.7
|
L
 92.1%
H
0.6
7.1
|
L
 -35.3%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
923.3
|
15.6
|
L
 -3.2%
H
15.4
16.3
|
L
 -6.9%
H
15.4
16.9
|
L
 -14.2%
H
15.4
19.8
|
L
 -22.7%
H
15.4
23.0
|
L
 82.2%
H
8.5
26.2
|
L
 -23.2%
H
0.5
26.2
|
L
 -72.9%
H
0.5
59.9
|
L
 -94.8%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
76.5
|
8.0
|
L
 4.1%
H
7.3
8.2
|
L
 26.8%
H
6.3
8.2
|
L
 -24%
H
4.6
11.4
|
L
 2.2%
H
4.6
20.3
|
L
 297.5%
H
0.7
20.3
|
L
 32.1%
H
0.7
20.3
|
L
 -79.0%
H
0.7
84
|
L
 -99.3%
H
0.7
1669.9
|
| Eledon Pharma Inc |
|
305.7
|
4.0
|
L
 0.3%
H
3.9
4.3
|
L
 13.8%
H
3.5
4.5
|
L
 1.8%
H
3.4
4.5
|
L
 27.7%
H
2.7
4.5
|
L
 52.3%
H
1.4
4.6
|
L
 175%
H
1.1
5.4
|
L
 -49.5%
H
1.1
8.5
|
L
 -99.6%
H
1.1
949.3
|
| Enanta Pharma Inc |
|
399.0
|
13.7
|
L
 -2.4%
H
13.7
14.7
|
L
 13.7%
H
12.1
14.7
|
L
 -1.7%
H
10.9
14.7
|
L
 8.5%
H
10.9
15.9
|
L
 92.7%
H
6.4
17.2
|
L
 -38.3%
H
4.1
22.5
|
L
 -71.3%
H
4.1
102
|
L
 -42.4%
H
4.1
127.8
|
| Entera Bio Ltd |
|
75.9
|
1.5
|
L
 -0.7%
H
1.5
1.7
|
L
 30.5%
H
1.2
2.8
|
L
 24.2%
H
1.2
2.8
|
L
 41.3%
H
0.9
2.8
|
L
 -21.4%
H
0.9
3.2
|
L
 85.5%
H
0.5
3.4
|
L
 -76.3%
H
0.5
6.6
|
L
H
0.5
10.2
|
| Evolus Inc |
|
459.0
|
7.0
|
L
 3.4%
H
6.8
7.2
|
L
 5.1%
H
6.4
7.2
|
L
 14.5%
H
6.0
7.2
|
L
 48.9%
H
3.9
7.2
|
L
 -25.7%
H
3.9
10.2
|
L
 -10.8%
H
3.9
17.8
|
L
 -50.1%
H
3.9
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
4,680.3
|
15.1
|
L
 -0.1%
H
14.7
15.3
|
L
 12.5%
H
13.4
15.8
|
L
 33.9%
H
10.9
15.8
|
L
 5.1%
H
8.7
24.3
|
L
 982.7%
H
1.2
24.3
|
L
 461.6%
H
1.0
24.3
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
811.7
|
3.2
|
L
 -0.3%
H
3.1
3.2
|
L
 -0.3%
H
3.1
3.2
|
L
 0.6%
H
3.1
3.2
|
L
 20.2%
H
1.8
3.2
|
L
 202.9%
H
1.0
4.2
|
L
 136.8%
H
0.7
4.2
|
L
 -85.8%
H
0.7
23.8
|
L
 -81.4%
H
0.7
82.7
|
| Eton Pharma Inc |
|
930.8
|
34.0
|
L
 1.5%
H
32.9
34.9
|
L
 5.0%
H
31.4
34.9
|
L
 4.3%
H
26.7
34.9
|
L
 42.7%
H
22.3
35.7
|
L
 151.5%
H
13.1
35.7
|
L
 758.1%
H
2.4
35.7
|
L
 475.0%
H
2.0
35.7
|
L
H
2.0
35.7
|
| Exelixis Inc |
|
13,289.1
|
52.9
|
L
 3.0%
H
51.7
53.1
|
L
 1.5%
H
50.8
53.1
|
L
 5.4%
H
48.1
53.9
|
L
 27.7%
H
40.8
53.9
|
L
 21.9%
H
33.8
53.9
|
L
 166.2%
H
18.6
53.9
|
L
 137.9%
H
14.9
53.9
|
L
 573.5%
H
7.2
53.9
|
| Hyperion DeFi Inc |
|
51.5
|
3.4
|
L
 -7.4%
H
3.4
3.7
|
L
 4.9%
H
3.2
4
|
L
 -6.1%
H
2.5
4.1
|
L
 -0.3%
H
2.5
5.0
|
L
 -38.0%
H
2.5
17.2
|
L
 -98.2%
H
0.0
208
|
L
 -99.2%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,207.3
|
14.4
|
L
 0.1%
H
14.3
14.9
|
L
 11.8%
H
12.8
14.9
|
L
 11.4%
H
11.3
14.9
|
L
 12.2%
H
11.3
15.3
|
L
 73.9%
H
8.4
19.1
|
L
 112.7%
H
3.9
31.0
|
L
 50%
H
2.2
31.0
|
L
 -55%
H
2.2
42.5
|
| Evotec SE (ADR) |
|
955.5
|
2.7
|
L
 2.7%
H
2.7
2.8
|
L
H
2.6
2.8
|
L
 -11.2%
H
2.6
3.1
|
L
 13.0%
H
2.3
3.4
|
L
 -29.4%
H
2.3
4.4
|
L
 -76.9%
H
2.3
13.5
|
L
 -87.7%
H
2.3
26.6
|
L
 31.2%
H
2.0
26.6
|
| Fortress Biotech Inc |
|
104.3
|
3.1
|
L
 -0.6%
H
3.1
3.4
|
L
 7.2%
H
2.9
3.4
|
L
 14.6%
H
2.5
3.4
|
L
 5.4%
H
2.2
3.4
|
L
 83.6%
H
1.7
4.5
|
L
 -63.9%
H
1.2
10.4
|
L
 -94.3%
H
1.2
57.2
|
L
 -92.3%
H
1.2
91.5
|
| Fennec Pharma Inc |
|
361.3
|
10.4
|
L
 1.0%
H
10
10.5
|
L
 16.1%
H
8.9
10.6
|
L
 4.7%
H
8.5
10.6
|
L
 39.6%
H
5.7
10.6
|
L
 28.9%
H
5.7
10.6
|
L
 16.1%
H
4.0
11.9
|
L
 53.4%
H
3.8
11.9
|
L
 374.9%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
28.1
|
6.9
|
L
 -0.4%
H
6.9
7.1
|
L
 0.4%
H
6.7
7.1
|
L
 -0.7%
H
6.6
8.0
|
L
 -1.7%
H
6.3
8.0
|
L
 28.5%
H
4.9
12.6
|
L
 -98.3%
H
4.5
95
|
L
 -99.0%
H
4.5
753.1
|
L
 -98.3%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
189.2
|
11.2
|
L
 -6.1%
H
10.7
12.2
|
L
 -12.5%
H
10.7
13.4
|
L
 92.4%
H
5.8
14.9
|
L
 65.1%
H
4.8
14.9
|
L
 629.4%
H
1.3
14.9
|
L
 -30.1%
H
1.3
53.8
|
L
 -91.3%
H
1.3
160.2
|
L
H
1.3
572.4
|
| Fulcrum Therapeutics Inc |
|
250.5
|
3.8
|
L
 -2.3%
H
3.7
4.0
|
L
 8.7%
H
3.5
4.0
|
L
 -42.8%
H
2.8
7.1
|
L
 -45.4%
H
2.8
8.4
|
L
 -47.6%
H
2.8
15.7
|
L
 19.7%
H
2.3
15.7
|
L
 -58.9%
H
2.3
33.1
|
L
H
2.3
33.1
|
| GH Research PLC |
|
1,687.8
|
24.6
|
L
 4.2%
H
23.4
24.8
|
L
 23.1%
H
20.0
24.8
|
L
 11.2%
H
19.5
25.9
|
L
 86.2%
H
12.8
25.9
|
L
 110.6%
H
11.3
25.9
|
L
 105.2%
H
5.1
25.9
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Galmed Pharma Ltd |
|
4.5
|
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 -1.7%
H
0.5
0.6
|
L
 1.7%
H
0.4
0.8
|
L
 1.7%
H
0.4
1.3
|
L
 -66.3%
H
0.4
2.3
|
L
 -98.5%
H
0.2
65.6
|
L
 -99.9%
H
0.2
615.6
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
1,354.2
|
22
|
L
 -4.1%
H
21.9
24.5
|
L
 6.9%
H
20.1
25.9
|
L
 -13.0%
H
18.6
26.5
|
L
 -4.6%
H
18.6
28.8
|
L
 552.8%
H
2.5
38.3
|
L
 759.4%
H
0.5
38.3
|
L
 344.4%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
1,120.3
|
17.4
|
L
 -0.8%
H
16.9
17.8
|
L
 -3.3%
H
16.8
18.9
|
L
 -16.3%
H
16.5
22.5
|
L
 57.3%
H
10.3
27.4
|
L
 13.5%
H
8.7
27.4
|
L
 -90.7%
H
8.7
353
|
L
 -92.6%
H
8.7
416
|
L
 -97.5%
H
8.7
2605
|
| Genelux Corp |
|
127.8
|
2.9
|
L
 -2.4%
H
2.8
3.0
|
L
 -5.9%
H
2.7
3.1
|
L
 -2.4%
H
2.7
3.2
|
L
 14.9%
H
2.3
3.3
|
L
 2.9%
H
2.3
8.5
|
L
 -91.7%
H
1.6
35.2
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
5.2
|
0.5
|
L
 -7.7%
H
0.5
0.5
|
L
 9.1%
H
0.4
0.6
|
L
 -41.5%
H
0.4
0.8
|
L
 -74.9%
H
0.4
2.0
|
L
 108.7%
H
0.1
13.0
|
L
 -35.1%
H
0.1
13.0
|
L
 -87.1%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
83.1
|
0.2
|
L
H
0.2
0.2
|
L
H
0.2
0.2
|
L
 -19.1%
H
0.1
0.2
|
L
 -54.1%
H
0.1
0.5
|
L
 -87.6%
H
0.1
3.9
|
L
 -87.4%
H
0.1
3.9
|
L
 -97.9%
H
0.1
15.2
|
L
H
0.1
27.2
|
| GT Biopharma Inc |
|
16.6
|
0.5
|
L
 -6.1%
H
0.4
0.5
|
L
 2.2%
H
0.4
0.6
|
L
 4.6%
H
0.4
0.6
|
L
 -2.1%
H
0.3
0.6
|
L
 -85.7%
H
0.3
3.9
|
L
 53.3%
H
0.2
10.7
|
L
 -97.0%
H
0.2
16.5
|
L
 -100.0%
H
0.2
2177.7
|
| Genmab (ADR) |
|
15,876.4
|
25.9
|
L
 -0.3%
H
25.8
26.2
|
L
 4.5%
H
24.9
26.2
|
L
 -3.8%
H
23.6
27.1
|
L
 0.7%
H
23.6
29.4
|
L
 25.1%
H
20.2
35.4
|
L
 -32.6%
H
17.2
42.7
|
L
 -38.1%
H
17.2
49.1
|
L
 44.1%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
43.6
|
1.9
|
L
 0.5%
H
1.7
1.9
|
L
 -1.1%
H
1.7
2.0
|
L
 219.0%
H
0.6
2.6
|
L
 176.1%
H
0.6
2.6
|
L
 -39.5%
H
0.6
10
|
L
 -69.0%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
4,913.8
|
7.2
|
L
 0.6%
H
7.1
7.2
|
L
 -4.9%
H
7.1
7.6
|
L
 -9.5%
H
7.1
8.2
|
L
 -6.1%
H
7.1
8.8
|
L
 -13.7%
H
7.1
11.1
|
L
 -19.1%
H
5.3
12.2
|
L
 -58.4%
H
5.3
17.9
|
L
 -55.1%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
22.5
|
1.0
|
L
 -1.9%
H
0.9
1.0
|
L
 -13.7%
H
0.9
1.2
|
L
 46.4%
H
0.7
2.5
|
L
 8.6%
H
0.5
2.5
|
L
 -17.2%
H
0.5
2.5
|
L
 -67.3%
H
0.5
3.8
|
L
 -97.5%
H
0.5
43.8
|
L
H
0.5
347
|
| Werewolf Therapeutics Inc |
|
18.5
|
0.4
|
L
 5.6%
H
0.4
0.4
|
L
 5.6%
H
0.3
0.4
|
L
 -13.6%
H
0.3
0.5
|
L
 -53.7%
H
0.3
1.1
|
L
 -69.6%
H
0.3
2.4
|
L
 -86.5%
H
0.3
8.2
|
L
 -97.4%
H
0.3
21.7
|
L
H
0.3
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,994.4
|
34.5
|
L
 0.9%
H
34.3
35.1
|
L
 1.8%
H
33.1
35.1
|
L
 14.3%
H
30.1
36.0
|
L
 24.8%
H
26.3
36.0
|
L
 7.9%
H
25.5
40.9
|
L
 -4.4%
H
18.6
41.6
|
L
 12.8%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,590.9
|
42.7
|
L
 -0.2%
H
42.4
44.1
|
L
 11.2%
H
38.5
44.5
|
L
 29.3%
H
32.5
44.5
|
L
 25.5%
H
28.5
44.5
|
L
 37.7%
H
28.5
54.9
|
L
 130.5%
H
7.6
59.2
|
L
 332.4%
H
5.4
59.2
|
L
 1008.6%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
1,765.9
|
10.3
|
L
 1.1%
H
10.2
10.3
|
L
 -2.1%
H
9.8
10.4
|
L
 -14.4%
H
9.8
12.0
|
L
 -26.6%
H
9.8
15.8
|
L
 -32.5%
H
9.8
19.5
|
L
 -4.7%
H
9.8
21.9
|
L
 -65.8%
H
7.4
43.9
|
L
 -25.7%
H
7.4
43.9
|
| ImmunityBio Inc |
|
8,169.4
|
7.8
|
L
 6.6%
H
7.3
8.0
|
L
 16.1%
H
6.7
8.0
|
L
 8.0%
H
6.7
8.3
|
L
 -17.0%
H
6.5
9.2
|
L
 182.6%
H
2.0
12.4
|
L
 190.0%
H
1.3
12.4
|
L
 -44.4%
H
1.2
15.7
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
3,492.8
|
36.3
|
L
 3.9%
H
35.1
37.2
|
L
 18.7%
H
30.5
37.2
|
L
 24.7%
H
26.8
37.2
|
L
 14.7%
H
26.8
38.1
|
L
 69.4%
H
20.5
39.3
|
L
 48.2%
H
13.5
47.7
|
L
 66.8%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
246.9
|
1.9
|
L
H
1.9
1.9
|
L
 12.0%
H
1.7
1.9
|
L
 10.7%
H
1.6
1.9
|
L
 7.5%
H
1.5
2.1
|
L
 12.7%
H
1.3
2.3
|
L
 -53.7%
H
0.8
4.2
|
L
 -89.3%
H
0.8
18.5
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
714.7
|
10.0
|
L
 1.3%
H
9.6
10.5
|
L
 14.9%
H
8.6
10.5
|
L
 14.4%
H
7.7
10.5
|
L
 14.0%
H
7.7
10.8
|
L
 350.2%
H
1.9
11.6
|
L
 284.7%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immuneering Corp (Class A) |
|
297.6
|
4.6
|
L
 1.3%
H
4.5
4.7
|
L
 12.2%
H
4.2
4.7
|
L
 -14.7%
H
3.9
6.0
|
L
 -10.2%
H
3.9
6.9
|
L
 88.5%
H
2.5
10.1
|
L
 -55.3%
H
1
11.1
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immunic Inc |
|
200.4
|
14.7
|
L
 -2.4%
H
14.4
15.5
|
L
 7.3%
H
13.5
15.5
|
L
 12.7%
H
11.6
15.8
|
L
 25.7%
H
8.5
15.8
|
L
 107.8%
H
5.1
15.8
|
L
 -1.9%
H
5.1
31.1
|
L
 -87.8%
H
5.1
145
|
L
 -99.5%
H
5.1
3900
|
| Incyte |
|
21,668.4
|
108.5
|
L
 3.9%
H
104.5
109.1
|
L
 8.7%
H
96.1
109.1
|
L
 11.6%
H
92.2
110.3
|
L
 19.9%
H
89.3
110.3
|
L
 61.3%
H
66.8
112.3
|
L
 73.7%
H
50.3
112.3
|
L
 27.4%
H
50.3
112.3
|
L
 32.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
402.0
|
3.6
|
L
 -4.3%
H
3.5
3.9
|
L
 -4.6%
H
3.5
4.9
|
L
 191.0%
H
1.1
6.0
|
L
 105.2%
H
0.9
6.0
|
L
 610%
H
0.3
13.4
|
L
 85.9%
H
0.3
13.4
|
L
 -76.1%
H
0.3
28.8
|
L
 -99.0%
H
0.3
8800
|
| Indivior PLC |
|
4,901.9
|
41.5
|
L
 3.8%
H
40
41.7
|
L
 9.1%
H
37.6
41.7
|
L
 10.5%
H
32.4
41.7
|
L
 41.1%
H
27.7
41.7
|
L
 197.3%
H
13.5
41.7
|
L
 81.9%
H
7.3
41.7
|
L
 1846.9%
H
2.0
41.7
|
L
 1149.1%
H
0.4
41.7
|
| InMed Pharma Inc |
|
5.1
|
1.6
|
L
 3.3%
H
1.5
1.6
|
L
 4.7%
H
1.5
1.6
|
L
 -9.9%
H
1.5
1.8
|
L
 104.0%
H
0.6
2.0
|
L
 -36.7%
H
0.6
5.5
|
L
 -91.7%
H
0.6
41.6
|
L
 -99.9%
H
0.6
1735
|
L
 -99.9%
H
0.6
32175
|
| Inovio Pharma Inc |
|
90.5
|
1.1
|
L
 -2.7%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -18.5%
H
1.1
1.4
|
L
 -31.7%
H
1.0
1.8
|
L
 -43.0%
H
1.0
3.0
|
L
 155.8%
H
0.3
14.8
|
L
 -87.3%
H
0.3
14.8
|
L
 -88.8%
H
0.3
33.8
|
| Insmed Inc |
|
22,425.2
|
103.5
|
L
 1.3%
H
102.3
107.2
|
L
 8.3%
H
94
107.2
|
L
 -2.6%
H
90.4
110.0
|
L
 -28.1%
H
90.4
166.2
|
L
 -1.9%
H
90.4
212.8
|
L
 418.3%
H
19.7
212.8
|
L
 271.6%
H
16.0
212.8
|
L
 906.4%
H
9.0
212.8
|
| Innoviva Inc |
|
1,744.8
|
23.6
|
L
 0.4%
H
23.6
24.2
|
L
 4.6%
H
22.2
24.2
|
L
 5.3%
H
21.2
24.2
|
L
 7.9%
H
21.2
24.5
|
L
 13.5%
H
16.5
25.1
|
L
 87.2%
H
12.2
25.1
|
L
 78.4%
H
10.6
25.1
|
L
 110.7%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
12,645.9
|
76.5
|
L
 0.7%
H
76.0
79
|
L
 4.7%
H
72.6
79
|
L
 1.3%
H
72.0
79
|
L
 8.1%
H
68.9
79.2
|
L
 103.1%
H
37.3
86.7
|
L
 93.0%
H
24.0
86.7
|
L
 102.5%
H
24.0
86.7
|
L
 224.2%
H
20.5
86.7
|
| Ironwood Pharma Inc (Class A) |
|
643.6
|
3.9
|
L
 1.3%
H
3.8
4
|
L
 6.8%
H
3.5
4
|
L
 -0.3%
H
3.1
4.0
|
L
 18.8%
H
3.0
4.9
|
L
 483.6%
H
0.7
5.8
|
L
 -64.2%
H
0.5
15.7
|
L
 -68.5%
H
0.5
15.7
|
L
 -63.9%
H
0.5
17.7
|
| I-Mab (ADR) |
|
184.4
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 6.0%
H
1.5
1.7
|
L
 -9.6%
H
1.5
1.9
|
L
 -39.2%
H
1.5
2.8
|
L
 -35.0%
H
1.5
6.8
|
L
 -47.5%
H
0.6
6.8
|
L
 -98.0%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
8.8
|
1.1
|
L
 -2.7%
H
1.0
1.1
|
L
 -3.6%
H
1.0
1.2
|
L
 8%
H
1.0
1.6
|
L
 54.3%
H
0.7
1.6
|
L
 -41.3%
H
0.7
2.4
|
L
 -44.3%
H
0.7
6.0
|
L
 -77.7%
H
0.7
6.0
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
178.4
|
1.9
|
L
 0.5%
H
1.9
1.9
|
L
 6.2%
H
1.8
2.0
|
L
 3.8%
H
1.7
2.0
|
L
 38.7%
H
1.2
2.6
|
L
 5.6%
H
1.2
2.6
|
L
 -40.1%
H
1.2
3.5
|
L
 -47.2%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Jaguar Health Inc |
|
2.2
|
2.7
|
L
 4.7%
H
2.5
2.8
|
L
 16.0%
H
2.1
2.8
|
L
 -7.9%
H
2.1
3.7
|
L
 -80.8%
H
2.1
16.8
|
L
 -97.2%
H
2.1
115.5
|
L
 -100.0%
H
2.1
36540
|
L
 -100.0%
H
2.1
21026250
|
L
 -100.0%
H
2.1
880621875
|
| Jazz Pharma PLC |
|
14,438.6
|
229.9
|
L
 -0.2%
H
228.3
234.1
|
L
 1.3%
H
220.7
234.1
|
L
 -4.2%
H
220.7
242
|
L
 26.1%
H
180.7
243.3
|
L
 115.3%
H
105
243.3
|
L
 84.1%
H
95.5
243.3
|
L
 29.9%
H
95.5
243.3
|
L
 58.5%
H
86.9
243.3
|
| Kala Pharma Inc |
|
55.8
|
3
|
L
 -3.9%
H
3.0
3.4
|
L
 -4.5%
H
2.8
3.7
|
L
 23.5%
H
2.0
3.7
|
L
 -74.3%
H
2.0
12.0
|
L
 -98.5%
H
2.0
1030
|
L
 -99.6%
H
2.0
1030
|
L
 -100.0%
H
2.0
15290.3
|
L
H
2.0
66943.3
|
| Kiniksa Pharma Ltd (Class A) |
|
4,549.3
|
59.1
|
L
 -0.6%
H
58.5
61.1
|
L
 13.1%
H
52.7
61.1
|
L
 11.1%
H
46.1
61.1
|
L
 28.4%
H
41.5
61.1
|
L
 105.9%
H
26.3
61.1
|
L
 282.5%
H
13.6
61.1
|
L
 312.9%
H
7.4
61.1
|
L
H
5.0
61.1
|
| Kiora Pharma Inc |
|
11.5
|
2.6
|
L
 -0.4%
H
2.5
2.7
|
L
 -1.2%
H
2.4
2.7
|
L
 1.2%
H
2.4
2.9
|
L
 27.0%
H
1.8
2.9
|
L
 -17.3%
H
1.8
3.3
|
L
 286.6%
H
0.4
5.6
|
L
 -98.6%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2340
|
| Karyopharm Therapeutics Inc |
|
206.7
|
9.1
|
L
 -5.5%
H
9.0
10.1
|
L
 0.2%
H
8.8
10.1
|
L
 11.8%
H
8.2
10.2
|
L
 36.9%
H
5
10.2
|
L
 110.6%
H
3.7
11.0
|
L
 -69.4%
H
0.6
30.3
|
L
 -94.1%
H
0.6
221.0
|
L
 -92.4%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
216.1
|
10.9
|
L
 -0.7%
H
10.9
11.5
|
L
 8.9%
H
10.1
11.5
|
L
 -2.4%
H
9.7
11.6
|
L
 -2.9%
H
9.7
12.6
|
L
 -20.6%
H
9.7
22.6
|
L
 -73.7%
H
9.1
73
|
L
 -75.5%
H
9.1
73
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
18.7
|
0.6
|
L
 -1.8%
H
0.5
0.6
|
L
 9.8%
H
0.5
0.6
|
L
 -20%
H
0.5
0.7
|
L
 -27.3%
H
0.5
1.0
|
L
 -22.2%
H
0.3
2.1
|
L
 21.7%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kazia Therapeutics Ltd (ADR) |
|
167.2
|
14.6
|
L
 -0.4%
H
14.4
15.3
|
L
 6.3%
H
13.3
15.3
|
L
 7.1%
H
10.6
15.3
|
L
 105.5%
H
6.8
15.3
|
L
 116.1%
H
4.9
17.4
|
L
 -76.2%
H
2.9
79
|
L
 -97.0%
H
2.9
614
|
L
 -96.3%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
13.6
|
0.6
|
L
 -3.5%
H
0.5
0.6
|
L
 -6.8%
H
0.5
0.6
|
L
 -15.4%
H
0.5
0.7
|
L
 -24.7%
H
0.5
1.1
|
L
 -43.3%
H
0.5
1.6
|
L
 -30.4%
H
0.5
6.9
|
L
 -91.7%
H
0.5
12.5
|
L
 -80.5%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
217.6
|
5.8
|
L
 2.5%
H
5.7
6.0
|
L
 8.4%
H
5.2
6.0
|
L
 17.7%
H
4.8
6.0
|
L
 43.2%
H
3.6
6.0
|
L
 -21.5%
H
3.6
9.0
|
L
 -34.9%
H
3.6
11.5
|
L
 -47.2%
H
1.5
12.6
|
L
 -46.7%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
5,709.9
|
284.9
|
L
 2.0%
H
278.7
288.5
|
L
 11.6%
H
245
288.5
|
L
 24.2%
H
222.8
288.5
|
L
 42.2%
H
188.7
288.5
|
L
 147.8%
H
111.7
288.5
|
L
 289.8%
H
49.3
288.5
|
L
 244.4%
H
46.8
288.5
|
L
 283.6%
H
36.9
288.5
|
| Atyr Pharma Inc |
|
54.9
|
0.6
|
L
 3.7%
H
0.5
0.6
|
L
 24.4%
H
0.4
0.6
|
L
 14.3%
H
0.4
0.6
|
L
 -32.5%
H
0.4
1.1
|
L
 -88.8%
H
0.4
7.3
|
L
 -74.4%
H
0.4
7.3
|
L
 -87.6%
H
0.4
13.1
|
L
 -98.6%
H
0.4
90.9
|
| Lipocine Inc |
|
20.4
|
2.5
|
L
 -2.4%
H
2.4
2.6
|
L
 7.4%
H
2.2
2.7
|
L
 9.3%
H
1.9
2.7
|
L
 -66.2%
H
1.8
9.3
|
L
 -21.3%
H
1.8
12.4
|
L
 -49.2%
H
1.8
12.4
|
L
 -89.3%
H
1.8
32.1
|
L
 -98.0%
H
1.8
125.3
|
| Liquidia Corp |
|
6,717.6
|
75.5
|
L
 2.0%
H
72.2
76.4
|
L
 11.1%
H
66.8
77.1
|
L
 23.9%
H
53.1
77.1
|
L
 112.8%
H
34.2
77.1
|
L
 469.7%
H
11.9
77.1
|
L
 739.3%
H
5.7
77.1
|
L
 2718.7%
H
2.3
77.1
|
L
H
2.3
77.1
|
| Lisata Therapeutics Inc |
|
31.3
|
3.4
|
L
 -0.9%
H
3.4
3.5
|
L
 -1.4%
H
3.4
3.6
|
L
 9.6%
H
3.1
4.0
|
L
 -31.5%
H
2.8
5.0
|
L
 43.9%
H
1.8
5.1
|
L
 -11.1%
H
1.8
5.1
|
L
 -85.4%
H
1.8
24.9
|
L
 -95.7%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
50.4
|
4.0
|
L
 3.1%
H
3.8
4.0
|
L
 1.0%
H
3.7
4.1
|
L
 12.9%
H
3.2
4.2
|
L
 76.3%
H
1.1
4.2
|
L
 28.7%
H
1.1
5.7
|
L
 -22.9%
H
1.1
12.0
|
L
 -73.6%
H
1.1
15.8
|
L
H
1.1
24.8
|
| Lexicon Pharma Inc |
|
986.1
|
2.2
|
L
 2.8%
H
2.2
2.3
|
L
 13.9%
H
2.0
2.3
|
L
 2.8%
H
1.8
2.3
|
L
 35.4%
H
1.5
2.5
|
L
 204.1%
H
0.7
2.5
|
L
 -6.3%
H
0.3
3.7
|
L
 -53.4%
H
0.3
6.3
|
L
 -84.1%
H
0.3
19.6
|
| Legend Biotech Corp (ADR) |
|
5,683.3
|
29.4
|
L
 0.3%
H
29.0
30.3
|
L
 -12.0%
H
27.4
34.1
|
L
 0.0%
H
24.8
37.5
|
L
 70.5%
H
16.7
37.5
|
L
 -13.2%
H
16.2
45.3
|
L
 -60.4%
H
16.2
77.3
|
L
 -28.1%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
5.3
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
H
0.6
0.8
|
L
 11.1%
H
0.6
0.9
|
L
 -13.6%
H
0.6
0.9
|
L
 -32.0%
H
0.5
7
|
L
 -99.8%
H
0.1
370
|
L
 -100.0%
H
0.1
2771.3
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
15.6
|
2.9
|
L
 6.6%
H
2.6
2.9
|
L
 8.5%
H
2.5
3.2
|
L
 22.6%
H
2.3
3.2
|
L
 39.5%
H
2
3.2
|
L
 -57.2%
H
1.8
24
|
L
 -98.6%
H
1.8
3318.8
|
L
 -99.8%
H
1.8
3318.8
|
L
 -100.0%
H
1.8
16560
|
| Madrigal Pharma Inc |
|
11,752.9
|
509.8
|
L
 -0.7%
H
509.1
527.7
|
L
 1.7%
H
485.6
527.7
|
L
 -1.5%
H
445.2
535.8
|
L
 13.9%
H
437.1
572.2
|
L
 80.1%
H
277.6
615
|
L
 114.5%
H
119.8
615
|
L
 404.5%
H
52.3
615
|
L
 4525.8%
H
6.6
615
|
| MediWound Ltd |
|
190.9
|
14.9
|
L
 5.5%
H
14.4
15.1
|
L
 7.1%
H
13.9
15.1
|
L
 -10.4%
H
13.5
16.9
|
L
 -12.0%
H
13.5
18.1
|
L
 -21.8%
H
13.5
21.3
|
L
 42.8%
H
7.1
24
|
L
 -56.6%
H
7.1
43.5
|
L
 -73.4%
H
7.1
60.1
|
| MEI Pharma Inc |
|
29.6
|
0.9
|
L
 -2.3%
H
0.8
0.9
|
L
 -5.4%
H
0.8
1.0
|
L
 -18.7%
H
0.7
1.1
|
L
 -26.3%
H
0.7
1.3
|
L
 -60.5%
H
0.7
9
|
L
 -86.8%
H
0.7
9
|
L
 -98.7%
H
0.7
71
|
L
 -96.8%
H
0.7
102.8
|
| Macrogenics Inc |
|
303.8
|
4.8
|
L
 1.9%
H
4.6
5.1
|
L
 23.2%
H
3.9
5.1
|
L
 5.5%
H
3.8
5.1
|
L
 63.7%
H
2.7
5.1
|
L
 262.1%
H
1.2
5.1
|
L
 -16.7%
H
1.0
21.9
|
L
 -81.3%
H
1.0
29.2
|
L
 -81.9%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
6.2
|
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 9.1%
H
0.3
0.4
|
L
 -20%
H
0.3
0.6
|
L
 12.5%
H
0.3
0.6
|
L
 -80.7%
H
0.2
2.8
|
L
 -80.4%
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
90.8
|
L
 3.7%
H
88.0
92.8
|
L
 15.1%
H
78.7
92.8
|
L
 5%
H
68.9
93.6
|
L
 14.5%
H
68.9
96.5
|
L
 427.9%
H
17.1
96.5
|
L
 773.1%
H
10.6
96.5
|
L
 -45.4%
H
5.1
173.4
|
L
H
5.1
336
|
| Mirum Pharma Inc |
|
7,011.0
|
115.0
|
L
 3.5%
H
109.2
115.9
|
L
 13.2%
H
101.2
115.9
|
L
 16.6%
H
90.6
115.9
|
L
 28.6%
H
84.9
115.9
|
L
 128.7%
H
47.9
115.9
|
L
 320.4%
H
23.1
115.9
|
L
 554.4%
H
12.8
115.9
|
L
H
6.5
115.9
|
| Milestone Pharma Inc |
|
158.1
|
1.3
|
L
 -2.3%
H
1.3
1.3
|
L
 -1.6%
H
1.3
1.4
|
L
 -9.9%
H
1.2
1.5
|
L
 0.8%
H
1
2.3
|
L
 -27.8%
H
1
3.1
|
L
 -59.7%
H
0.6
3.9
|
L
 -78.6%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,472.3
|
20
|
L
 -5.8%
H
18.9
20.5
|
L
 5.4%
H
18.8
23.3
|
L
 10.0%
H
17
23.3
|
L
 18.6%
H
15.8
23.3
|
L
 -55.4%
H
6.0
62.8
|
L
 -22.7%
H
6.0
65.0
|
L
 92.7%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
1,186.4
|
3.8
|
L
 -2.3%
H
3.8
4.0
|
L
 -0.8%
H
3.8
4.1
|
L
 13.6%
H
3.3
4.1
|
L
 57.4%
H
2.2
4.3
|
L
 1.1%
H
2.2
6.5
|
L
 -2.3%
H
2.2
7.6
|
L
 -15.0%
H
2.2
7.6
|
L
 -38.1%
H
0.7
7.6
|
| Mind Medicine Inc |
|
4,595.0
|
42.1
|
L
 16.5%
H
39.3
44.5
|
L
 74.4%
H
23.8
44.5
|
L
 87.2%
H
21.7
44.5
|
L
 132.8%
H
17.1
44.5
|
L
 534.5%
H
6.4
44.5
|
L
 1176.7%
H
2.4
44.5
|
L
 -19.1%
H
2.1
58.8
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
65.5
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 -5%
H
1.2
1.4
|
L
 -8.3%
H
1.2
1.5
|
L
 1.5%
H
1.2
2.0
|
L
 -42.9%
H
1.1
2.7
|
L
 -65.9%
H
1.1
4.7
|
L
 -81.3%
H
1.1
14.5
|
| TNF Pharma Inc |
|
29.9
|
3.8
|
L
 -2.1%
H
3.7
4.0
|
L
 -1.6%
H
3.7
4.2
|
L
 -8.9%
H
3.5
4.8
|
L
 0.3%
H
3.1
5.5
|
L
 -72.4%
H
2.5
17.4
|
L
 -99.9%
H
2.5
6387
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,814.6
|
32.6
|
L
 3.9%
H
31.5
33.0
|
L
 8.1%
H
29.6
33.0
|
L
 -7.9%
H
29.1
37.3
|
L
 8.7%
H
27.9
42.2
|
L
 79.2%
H
17.7
42.2
|
L
 167.5%
H
5.6
42.2
|
L
 229.6%
H
5.6
42.2
|
L
H
5.6
42.2
|
| Neurocrine Biosciences Inc |
|
16,697.3
|
166.1
|
L
 2.9%
H
162.3
168.6
|
L
 6.2%
H
155.7
168.6
|
L
 6.0%
H
154.1
169.6
|
L
 30.7%
H
125.1
169.6
|
L
 32%
H
122.1
169.6
|
L
 72.3%
H
84.2
169.6
|
L
 65.6%
H
71.9
169.6
|
L
 272.4%
H
37.3
169.6
|
| Minerva Neurosciences Inc |
|
201.7
|
4.3
|
L
 -0.5%
H
4.2
4.5
|
L
 -0.9%
H
4.1
4.7
|
L
 -17.7%
H
4.1
5.5
|
L
 -33.9%
H
4.1
7.6
|
L
 144.6%
H
1.6
12.5
|
L
 -29.1%
H
1.2
13.5
|
L
 -78.0%
H
1.2
20.6
|
L
 -95.0%
H
1.2
121.7
|
| Nektar Therapeutics |
|
2,190.7
|
64.8
|
L
 -2.8%
H
63.9
68.0
|
L
 7.6%
H
59.3
68.0
|
L
 -2.7%
H
54.1
68.0
|
L
 -12.8%
H
54.1
109
|
L
 579.7%
H
16.6
109
|
L
 645.3%
H
6.2
109
|
L
 -74.1%
H
6.2
290.6
|
L
 -72.2%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
19.3
|
3.6
|
L
 1.4%
H
3.4
3.6
|
L
 11.8%
H
3.1
3.6
|
L
 13.6%
H
2.8
3.7
|
L
 46.5%
H
1.8
5.1
|
L
 -84.6%
H
1.8
30.8
|
L
 -99.1%
H
1.2
612
|
L
 -99.7%
H
1.2
1488
|
L
H
1.2
2940
|
| Nurix Therapeutics Inc |
|
1,995.7
|
19.3
|
L
 2.3%
H
18.9
20.0
|
L
 13.1%
H
17.0
20.0
|
L
 10.3%
H
14.2
20.0
|
L
 31.4%
H
14.0
20.0
|
L
 61.1%
H
8.2
22.5
|
L
 92.8%
H
4.2
29.6
|
L
 -34.4%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
27.4
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 8.6%
H
0.7
0.9
|
L
 -7.3%
H
0.7
0.9
|
L
 2.7%
H
0.6
1.0
|
L
 -64.3%
H
0.6
2.4
|
L
 -51.3%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
152.4
|
3.6
|
L
 -5.3%
H
3.1
3.9
|
L
 -10.3%
H
3.1
4.2
|
L
 10.6%
H
3.1
5.1
|
L
 101.1%
H
1.8
5.1
|
L
 14.8%
H
1.6
5.1
|
L
 -29.1%
H
1.1
54
|
L
 -97.3%
H
1.1
262.4
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
649.3
|
24.5
|
L
 39.5%
H
17.6
24.7
|
L
 105.0%
H
12.0
24.7
|
L
 136.5%
H
9.2
24.7
|
L
 196.4%
H
7.2
24.7
|
L
 207.5%
H
5.6
24.7
|
L
 44.4%
H
4.4
24.7
|
L
H
3.1
24.7
|
L
H
3.1
24.7
|
| Nextcure Inc |
|
6.4
|
1.8
|
L
 -2.2%
H
1.7
1.9
|
L
 -9.7%
H
1.7
2.3
|
L
 -77.4%
H
1.7
7.9
|
L
 -83%
H
1.7
13.5
|
L
 -68.6%
H
1.7
15.7
|
L
 -90.8%
H
1.7
30.8
|
L
 -98.1%
H
1.7
110.2
|
L
H
1.7
1308
|
| Ocugen Inc |
|
470.5
|
1.4
|
L
 0.7%
H
1.4
1.5
|
L
 17.8%
H
1.2
1.5
|
L
 3.7%
H
1.2
1.5
|
L
 -33.8%
H
1.2
2.1
|
L
 41.8%
H
0.9
2.7
|
L
 162.3%
H
0.3
2.7
|
L
 -81.6%
H
0.3
17.7
|
L
 -98.7%
H
0.2
268.2
|
| Oculis Holding AG |
|
698.1
|
11.6
|
L
 -1.4%
H
11.4
11.8
|
L
 1.0%
H
10.9
12.2
|
L
 -60.8%
H
10.5
30.7
|
L
 -53.0%
H
10.5
34.5
|
L
 -41.2%
H
10.5
34.5
|
L
 -6.9%
H
9.1
34.5
|
L
 19.1%
H
6.3
34.5
|
L
H
6.3
34.5
|
| Ocular Therapeutix Inc |
|
2,156.8
|
9.9
|
L
 -2.7%
H
9.7
10.4
|
L
 10.2%
H
8.6
10.6
|
L
 19.7%
H
8.1
10.6
|
L
 21.6%
H
7.4
10.6
|
L
 17.7%
H
6.2
16.4
|
L
 102.3%
H
2
16.4
|
L
 -31.6%
H
2
16.4
|
L
 82.1%
H
2
24.3
|
| Opus Genetics Inc |
|
306.3
|
3.7
|
L
 -9.1%
H
3.7
4.1
|
L
 -4.9%
H
3.7
4.3
|
L
 -12.9%
H
3.7
4.7
|
L
 -19.2%
H
3.7
5.8
|
L
 307.7%
H
0.9
5.8
|
L
 -5.1%
H
0.7
5.8
|
L
 -23.2%
H
0.7
7
|
L
 -97.1%
H
0.7
340.8
|
| Olema Pharma Inc |
|
973.1
|
11.1
|
L
 5.8%
H
10.3
11.7
|
L
 21.2%
H
9.1
11.7
|
L
 -18.6%
H
9.1
14.0
|
L
 -20.3%
H
9.1
17.5
|
L
 165.9%
H
4.1
36.3
|
L
 41.6%
H
2.9
36.3
|
L
 -58.2%
H
2
36.3
|
L
H
2
60.3
|
| Omeros Corp |
|
765.7
|
10.6
|
L
 1.0%
H
10.5
10.8
|
L
 11.6%
H
9.3
10.8
|
L
 -7.7%
H
6.7
12.0
|
L
 -0.8%
H
6.7
15.3
|
L
 231.7%
H
3.0
17.7
|
L
 92.7%
H
0.9
17.7
|
L
 -31.5%
H
0.9
17.7
|
L
 -3.6%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
976.2
|
9.4
|
L
 5.8%
H
8.9
9.6
|
L
 13.5%
H
8.3
9.6
|
L
 13.3%
H
7.3
9.6
|
L
 -15.3%
H
7.2
13.0
|
L
 -5.7%
H
7.2
14.9
|
L
 45.3%
H
3.9
16.7
|
L
 -47.4%
H
2.4
26.7
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
176.0
|
4.3
|
L
 3.1%
H
4.1
4.3
|
L
 14.1%
H
3.8
4.3
|
L
 7.8%
H
3.6
4.3
|
L
 21.1%
H
3.2
5.0
|
L
 103.8%
H
2.0
5.0
|
L
 32.3%
H
1.7
5.0
|
L
 -69.5%
H
1.7
31.5
|
L
 -47.2%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
249.6
|
1.7
|
L
 -1.2%
H
1.6
1.8
|
L
 7.0%
H
1.4
1.9
|
L
 441.9%
H
0.4
1.9
|
L
 425%
H
0.2
1.9
|
L
H
0.2
3.0
|
L
 -99.8%
H
0.2
740.0
|
L
 -99.8%
H
0.2
1308
|
L
 -100.0%
H
0.2
17568
|
| Ovid Therapeutics Inc |
|
466.6
|
2.5
|
L
 7.8%
H
2.3
2.5
|
L
 5.9%
H
2.2
2.5
|
L
 1.2%
H
2.2
2.8
|
L
 -2.0%
H
2.0
3.1
|
L
 762.1%
H
0.3
3.1
|
L
 -33.0%
H
0.2
4.1
|
L
 -40.9%
H
0.2
4.4
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,272.1
|
31.4
|
L
 2.7%
H
30.9
32.2
|
L
 -1.6%
H
30.5
32.5
|
L
 -5.7%
H
28.3
35.0
|
L
 -41.7%
H
28.3
60.1
|
L
 28.2%
H
24.3
60.1
|
L
 132.8%
H
9.4
60.1
|
L
 9.3%
H
9.4
60.1
|
L
 53.7%
H
9.4
60.1
|
| Palisade Bio Inc |
|
333.7
|
1.9
|
L
 -1.0%
H
1.9
2.0
|
L
 7.9%
H
1.7
2.0
|
L
 -1.5%
H
1.6
2.2
|
L
 0.5%
H
1.5
2.9
|
L
 174.3%
H
0.5
2.9
|
L
 -92.6%
H
0.4
36.6
|
L
 -99.9%
H
0.4
3427.5
|
L
 -100.0%
H
0.4
594000
|
| Puma biotech Inc |
|
404.7
|
8.0
|
L
 -1.1%
H
7.8
8.4
|
L
 10.9%
H
7.1
8.4
|
L
 12.3%
H
6.8
8.4
|
L
 27.2%
H
6
8.4
|
L
 137.3%
H
3.0
8.4
|
L
 123.9%
H
2.1
8.4
|
L
 -18.2%
H
1.6
10.0
|
L
 -76.4%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
942.8
|
24.0
|
L
 1.9%
H
23.5
24.2
|
L
 5%
H
22
24.2
|
L
 2.6%
H
22
25.2
|
L
 5.8%
H
21.9
27.1
|
L
 -3.2%
H
18.8
27.6
|
L
 -40.2%
H
11.2
40.7
|
L
 -60.3%
H
11.2
82.2
|
L
 -40.1%
H
11.2
82.2
|
| Processa Pharma Inc |
|
5.3
|
1.9
|
L
 -4.5%
H
1.9
2.1
|
L
 -7.7%
H
1.9
2.3
|
L
 -27.2%
H
1.9
3
|
L
 -17.9%
H
1.9
3.5
|
L
 -72.0%
H
1.8
14.3
|
L
 -99.2%
H
1.8
450
|
L
 -99.9%
H
1.8
4495.5
|
L
 -100.0%
H
1.8
17937.5
|
| PDS biotech Corp |
|
48.6
|
0.9
|
L
 -4.4%
H
0.9
0.9
|
L
 -9.4%
H
0.9
1
|
L
 -27.5%
H
0.9
1.3
|
L
 52.6%
H
0.5
1.6
|
L
 -43.5%
H
0.5
1.7
|
L
 -84.0%
H
0.5
6.9
|
L
 -92.1%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| Phathom Pharma Inc |
|
846.2
|
10.6
|
L
 -2.3%
H
10.6
11.2
|
L
 1.7%
H
10.5
11.4
|
L
 -6.4%
H
8.8
11.5
|
L
 0.4%
H
8.8
13.7
|
L
 12.0%
H
7.6
18.3
|
L
 -19.3%
H
2.2
19.7
|
L
 -69.5%
H
2.2
37.2
|
L
H
2.2
64.5
|
| Pharvaris NV |
|
2,326.3
|
33.3
|
L
 0.3%
H
33.0
34.1
|
L
 5.8%
H
31.4
34.4
|
L
 12.2%
H
28.5
34.4
|
L
 29.5%
H
25.0
34.4
|
L
 91.1%
H
16.7
34.4
|
L
 187.0%
H
11.5
34.4
|
L
 70.5%
H
1.8
34.4
|
L
H
1.8
42.9
|
| Praxis Precision Medicines Inc |
|
8,612.9
|
308.9
|
L
 1.2%
H
302.5
316.6
|
L
 20.1%
H
259.1
316.6
|
L
 -10.1%
H
238.8
366.5
|
L
 5.0%
H
238.8
366.5
|
L
 642.1%
H
37.2
366.5
|
L
 1706.7%
H
12.8
366.5
|
L
 6.5%
H
11.9
366.5
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
4.3
|
1.4
|
L
 -2.8%
H
1.4
1.5
|
L
 -23.4%
H
1.4
2.0
|
L
 -5.4%
H
1.3
5.4
|
L
 -38.2%
H
1.3
5.4
|
L
 -3.4%
H
0.6
5.4
|
L
 -95.2%
H
0.2
158.5
|
L
 -99.2%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
190.7
|
1.8
|
L
 -4.2%
H
1.8
1.9
|
L
 19.1%
H
1.5
2.0
|
L
 16.0%
H
1.4
2.0
|
L
 16.8%
H
1.4
2.2
|
L
 -7.2%
H
1.3
3.1
|
L
 9.0%
H
1.1
4.6
|
L
 -74.4%
H
0.5
9.1
|
L
 -64.2%
H
0.5
24
|
| Plus Therapeutics Inc |
|
27.3
|
4.0
|
L
 -2.9%
H
3.9
4.2
|
L
 -13.4%
H
3.9
4.6
|
L
 -39.9%
H
3.9
7.1
|
L
 -35.1%
H
2.9
8
|
L
 -13.9%
H
2.9
23.4
|
L
 -94.7%
H
2.9
80.3
|
L
 -99.6%
H
2.9
1050
|
L
 -100.0%
H
2.9
429375
|
| PTC Therapeutics Inc |
|
7,001.8
|
84.4
|
L
 2.8%
H
81.8
85.2
|
L
 15.2%
H
74.9
85.2
|
L
 22.7%
H
67.2
85.2
|
L
 27.1%
H
63.2
85.2
|
L
 70.2%
H
43.2
87.5
|
L
 103.5%
H
17.5
87.5
|
L
 94.4%
H
17.5
87.5
|
L
 1105.9%
H
4.0
87.5
|
| Pulmatrix Inc |
|
5.6
|
1.5
|
L
 2%
H
1.5
1.6
|
L
 2.7%
H
1.4
1.6
|
L
 14.2%
H
1.2
1.6
|
L
 -32.3%
H
1.2
2.3
|
L
 -77.9%
H
1.2
8.0
|
L
 -43.1%
H
1.2
10.4
|
L
 -92.4%
H
1.2
22
|
L
 -99.7%
H
1.2
1396
|
| Polypid Ltd |
|
91.3
|
4.8
|
L
 -4.6%
H
4.7
5.0
|
L
 2.2%
H
4.6
5.2
|
L
 -5.2%
H
4.4
5.2
|
L
 14.7%
H
4.0
5.2
|
L
 29.4%
H
3.1
5.2
|
L
 -56.0%
H
2.3
12.3
|
L
 -98.2%
H
2.3
289.2
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
137.5
|
2.2
|
L
 3.3%
H
2.1
2.3
|
L
 24%
H
1.8
2.3
|
L
 10.7%
H
1.5
2.3
|
L
 52.8%
H
1.3
2.9
|
L
 79.3%
H
1.0
5.6
|
L
 -18.4%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
916.7
|
13.0
|
L
 0.9%
H
12.9
13.4
|
L
 3.8%
H
12.6
13.4
|
L
 3.0%
H
12.0
13.8
|
L
 -18.9%
H
11.8
18.4
|
L
 25.8%
H
9.5
21.3
|
L
 18.1%
H
6.7
21.3
|
L
 17.1%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
1.6
|
1.8
|
L
 -1.1%
H
1.7
1.8
|
L
 6.7%
H
1.6
1.9
|
L
 -39.2%
H
1.4
3.1
|
L
 -56.0%
H
1.4
5
|
L
 -92.4%
H
1.4
29
|
L
 -100.0%
H
1.4
7200
|
L
 -100.0%
H
1.4
23280
|
L
 -100.0%
H
1.4
182000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
68.2
|
0.3
|
L
H
0.3
0.4
|
L
 -22.7%
H
0.3
0.4
|
L
 17.2%
H
0.3
0.5
|
L
 -50%
H
0.3
0.7
|
L
 -97.4%
H
0.3
13.7
|
L
 -92.5%
H
0.3
17.2
|
L
 -98.4%
H
0.3
22.5
|
L
H
0.3
110
|
| Quoin Pharma Ltd (ADR) |
|
7.7
|
3.8
|
L
 17.9%
H
3.6
5.0
|
L
 -14.1%
H
3.3
5.1
|
L
 -19.7%
H
3.3
5.2
|
L
 -53.1%
H
3.3
10.8
|
L
 -55.4%
H
3.3
41.8
|
L
 -99.9%
H
3.3
8400
|
L
 -100.0%
H
3.3
3003840
|
L
H
3.3
3003840
|
| Ultragenyx Pharmaceutical Inc |
|
2,867.0
|
29.1
|
L
 1.2%
H
29.0
30.1
|
L
 17.1%
H
25.1
30.1
|
L
 24.5%
H
21.3
30.1
|
L
 43.6%
H
18.3
30.1
|
L
 -21.0%
H
18.3
42.4
|
L
 -42.0%
H
18.3
60.4
|
L
 -68.9%
H
18.3
104.4
|
L
 -44.0%
H
18.3
179.7
|
| Regeneron Pharma |
|
65,359.8
|
623.4
|
L
 0.9%
H
619.3
631.2
|
L
 1.4%
H
594.9
631.2
|
L
 -2.4%
H
591.5
648.5
|
L
 -15.4%
H
591.5
781.2
|
L
 21.8%
H
514.8
821.1
|
L
 -20.0%
H
476.5
1211.2
|
L
 17.7%
H
476.5
1211.2
|
L
 74.6%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
4,232.8
|
8.6
|
L
 -22.7%
H
8.6
11
|
L
 -48.8%
H
8.6
17.0
|
L
 -66.8%
H
8.6
27.5
|
L
 -66.1%
H
8.6
40
|
L
 -63.9%
H
8.6
69
|
L
 1280.6%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
7,806.8
|
138.4
|
L
 9.5%
H
127.2
140.3
|
L
 5.1%
H
124.9
140.3
|
L
 20.3%
H
112
140.3
|
L
 19.0%
H
101.0
141.5
|
L
 15.2%
H
101.0
175.8
|
L
 -7.5%
H
101.0
211.1
|
L
 -28.3%
H
101.0
327.3
|
L
 480.5%
H
22.5
327.3
|
| Regenxbio Inc |
|
515.4
|
10.0
|
L
 0.2%
H
9.9
11.0
|
L
 43.9%
H
7.2
11.0
|
L
 57.0%
H
5.9
11.0
|
L
 19.5%
H
5.5
11.4
|
L
 26.8%
H
5.5
16.2
|
L
 -47.2%
H
5.0
28.8
|
L
 -74.1%
H
5.0
46.5
|
L
 0.5%
H
5.0
85.1
|
| Rigel Pharma |
|
676.3
|
36.6
|
L
 2.6%
H
35.8
37.0
|
L
 12.6%
H
32.4
37.0
|
L
 26.0%
H
28.5
37.0
|
L
 37.9%
H
25.1
37.0
|
L
 94%
H
18.1
52.2
|
L
 2075.6%
H
0.7
52.2
|
L
 764.1%
H
0.6
52.2
|
L
 1379.8%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
683.5
|
6.5
|
L
 -3.8%
H
6.5
6.9
|
L
 -0.6%
H
6.5
7.1
|
L
 -7.5%
H
5.6
7.4
|
L
 11.1%
H
5.6
8
|
L
 967.2%
H
0.5
8
|
L
 163.6%
H
0.2
8
|
L
 -79.8%
H
0.2
38.7
|
L
 -38.6%
H
0.2
54
|
| RenovoRx Inc |
|
42.8
|
1.0
|
L
 4.4%
H
0.9
1.0
|
L
 8.0%
H
0.9
1.0
|
L
 8.0%
H
0.8
1.0
|
L
 -14.4%
H
0.8
1.3
|
L
 -32.6%
H
0.7
1.5
|
L
 -50.3%
H
0.6
3.3
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
24,462.4
|
34.0
|
L
 5.6%
H
32
34.5
|
L
 11.8%
H
30.5
34.5
|
L
 13.5%
H
27.9
34.5
|
L
 21.8%
H
26.0
34.5
|
L
 195.7%
H
10.7
34.5
|
L
 247.0%
H
8.2
34.5
|
L
 243.9%
H
2.5
34.5
|
L
H
2.5
34.5
|
| Royalty Pharma PLC (Class A) |
|
24,060.9
|
54.3
|
L
 -1.9%
H
54.2
55.6
|
L
 0.1%
H
51.2
55.6
|
L
 -0.4%
H
51.2
56.5
|
L
 19.0%
H
45.2
56.5
|
L
 53.3%
H
34.1
56.5
|
L
 75.4%
H
24.1
56.5
|
L
 28.7%
H
24.1
56.5
|
L
H
24.1
56.5
|
| Rezolute Inc |
|
484.4
|
5.0
|
L
 2.9%
H
4.9
5.3
|
L
 10.1%
H
4.6
5.3
|
L
 54.8%
H
3.2
5.3
|
L
 109.6%
H
2.5
5.3
|
L
 24.8%
H
1.1
11.5
|
L
 126.6%
H
0.7
11.5
|
L
 -61.3%
H
0.7
17.4
|
L
 -89.6%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.7
|
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 15.2%
H
0.8
0.9
|
L
 -7.1%
H
0.8
1.1
|
L
 3.4%
H
0.7
1.1
|
L
 -51.9%
H
0.7
3.3
|
L
 -97.9%
H
0.7
82
|
L
 -100.0%
H
0.7
11180
|
L
 -100.0%
H
0.7
16540
|
| Sunshine Biopharma Inc |
|
4.3
|
2.0
|
L
H
2.0
2.1
|
L
 -4.7%
H
2
2.2
|
L
 -57.6%
H
2
4.6
|
L
 -80%
H
2
23.2
|
L
 -85.7%
H
2
24.3
|
L
 -100.0%
H
2
12900
|
L
 -100.0%
H
2
676840.8
|
L
 -100.0%
H
2
45037037.0
|
| Scilex Holding Co |
|
48.2
|
6.9
|
L
 -0.3%
H
6.6
7.1
|
L
 16.7%
H
5.5
7.5
|
L
 12.3%
H
5.4
9.7
|
L
 -6.7%
H
4.2
12.3
|
L
 37.8%
H
4.2
34.3
|
L
 8.9%
H
0.2
34.3
|
L
 -30.9%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
38.4
|
3.9
|
L
 1.3%
H
3.8
3.9
|
L
 -5.4%
H
3.7
4.2
|
L
 -33.9%
H
3.7
6.2
|
L
 -44.8%
H
3.7
9.1
|
L
 -33.7%
H
3.7
10.5
|
L
 -83.0%
H
3.7
31.0
|
L
 -93.6%
H
3.7
65.7
|
L
 -97.8%
H
3.7
440.8
|
| Shuttle Pharma Holdings Inc |
|
2.2
|
3.7
|
L
 -3.9%
H
3.6
3.9
|
L
 -9.6%
H
3.2
4.6
|
L
 536.2%
H
0.4
4.7
|
L
 314.6%
H
0.4
4.7
|
L
 5.4%
H
0.4
5.6
|
L
 -98.4%
H
0.4
254
|
L
H
0.4
25252
|
L
H
0.4
25252
|
| SIGA Tech Inc |
|
309.8
|
4.3
|
L
 0.5%
H
4.3
4.4
|
L
 0.5%
H
4.3
4.4
|
L
 -7.7%
H
4.2
4.8
|
L
 -13.4%
H
4.1
5.5
|
L
 -30.2%
H
4.1
9.6
|
L
 -16.3%
H
4.1
12.8
|
L
 -29.2%
H
4.1
27.0
|
L
 380%
H
0.8
27.0
|
| SILO Pharma Inc |
|
6.7
|
6.2
|
L
 -0.3%
H
5.9
6.3
|
L
 -0.5%
H
5.7
6.5
|
L
 1494.9%
H
0.3
6.8
|
L
 1677.1%
H
0.3
6.8
|
L
 936.7%
H
0.2
6.8
|
L
 197.6%
H
0.2
6.8
|
L
 -55.6%
H
0.2
496
|
L
 -87.6%
H
0.2
496
|
| Sol-Gel Tech Ltd |
|
239.9
|
73.4
|
L
 3%
H
71.3
80.8
|
L
 0.7%
H
69.5
80.8
|
L
 -4.3%
H
66
81.5
|
L
 10.9%
H
62.5
93.5
|
L
 880.0%
H
7.0
98.0
|
L
 2222.8%
H
0.3
98.0
|
L
 492.4%
H
0.3
98.0
|
L
H
0.3
98.0
|
| SELLAS Life Sciences Grp Inc |
|
1,803.1
|
9.2
|
L
 1.1%
H
8.8
9.3
|
L
 21.8%
H
7.5
9.3
|
L
 17.9%
H
7.1
9.5
|
L
 67.3%
H
4.0
9.5
|
L
 436.3%
H
1.4
9.5
|
L
 449.1%
H
0.5
9.5
|
L
 -31.7%
H
0.5
15.1
|
L
 -100.0%
H
0.5
63900
|
| Soligenix Inc |
|
5.8
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 -7.1%
H
0.4
0.4
|
L
H
0.4
1.1
|
L
 -67.8%
H
0.3
1.4
|
L
 -76.4%
H
0.3
6.2
|
L
 -96.6%
H
0.3
85.3
|
L
 -99.9%
H
0.3
316.8
|
L
 -100.0%
H
0.3
2040.1
|
| Sonoma Pharma Inc |
|
5.5
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 4.6%
H
1.0
1.3
|
L
 4.6%
H
1.0
1.3
|
L
 -54.9%
H
0.9
2.9
|
L
 -60.9%
H
0.9
6.9
|
L
 -1.7%
H
0.1
6.9
|
L
 -85.1%
H
0.1
13.4
|
L
 -96.9%
H
0.1
74.2
|
| Synaptogenix Inc |
|
25.3
|
3.4
|
L
 -4.2%
H
3.3
3.8
|
L
 -14.0%
H
3.3
4.1
|
L
 -25.2%
H
3.3
4.8
|
L
 -42.6%
H
3.3
7.2
|
L
 -5.3%
H
3.3
12.0
|
L
 285.2%
H
0.1
12.0
|
L
 -68.3%
H
0.1
14.5
|
L
H
0.1
14.5
|
| SciSparc Ltd |
|
3.4
|
5.9
|
L
 -15.3%
H
5.7
6.8
|
L
 -27.2%
H
5.7
8.1
|
L
 37.2%
H
4.3
15.8
|
L
 29.7%
H
3.0
15.8
|
L
 -89.7%
H
3.0
80.1
|
L
 -99.8%
H
3.0
3145.0
|
L
H
3.0
41769
|
L
H
3.0
41769
|
| ARS Pharma Inc |
|
1,046.7
|
10.5
|
L
 2.5%
H
10.4
10.9
|
L
 8.7%
H
9.5
10.9
|
L
 32.8%
H
7.9
10.9
|
L
 37.4%
H
7.0
10.9
|
L
 -36.4%
H
6.7
18.9
|
L
 67.8%
H
2.6
18.9
|
L
 -66.0%
H
2.6
35.6
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
39.1
|
0.8
|
L
 -41.4%
H
0.7
1.5
|
L
 47.2%
H
0.4
1.8
|
L
 -45.1%
H
0.4
1.8
|
L
 -79.0%
H
0.4
3.7
|
L
 -70.8%
H
0.4
5.3
|
L
 95%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,763.1
|
16.7
|
L
 -3.2%
H
16.7
17.4
|
L
 5.8%
H
16.2
18.2
|
L
 -0.6%
H
14.7
18.2
|
L
 -5.7%
H
14.7
23.9
|
L
 -11.5%
H
10.4
25.3
|
L
 -85.4%
H
10.4
173.3
|
L
 -78.7%
H
10.4
173.3
|
L
 -6.6%
H
10.4
181.8
|
| Sutro Biopharma Inc |
|
497.6
|
30.0
|
L
 2.9%
H
29.3
31.8
|
L
 6.6%
H
27.7
32.8
|
L
 17.4%
H
23.6
32.8
|
L
 40.8%
H
21.1
43.9
|
L
 275.8%
H
6.7
43.9
|
L
 -41.2%
H
5.2
61.3
|
L
 -83.8%
H
5.2
237
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,619.9
|
45.1
|
L
 1.5%
H
44.1
45.5
|
L
 3.6%
H
42.5
45.5
|
L
 -6.4%
H
42.5
48.7
|
L
 -8.4%
H
42.5
53.0
|
L
 41.1%
H
30.8
59.7
|
L
 38.3%
H
22
59.7
|
L
 41.4%
H
22
59.7
|
L
 136.1%
H
13.1
61.3
|
| Savara Inc |
|
1,194.7
|
5.8
|
L
 0.9%
H
5.7
5.9
|
L
 10%
H
5.3
5.9
|
L
 16.1%
H
4.7
5.9
|
L
 14.8%
H
4.7
6.2
|
L
 169.9%
H
2.0
7
|
L
 103.8%
H
1.9
7
|
L
 239.0%
H
1.0
7
|
L
 -81.7%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
11.3
|
2.5
|
L
 2.4%
H
2.5
2.6
|
L
 9.5%
H
2.2
2.6
|
L
 53.0%
H
1.4
2.8
|
L
 72.8%
H
1.3
2.8
|
L
 38.0%
H
0.0
7.0
|
L
 -54.2%
H
0.0
9.4
|
L
 -92.7%
H
0.0
57
|
L
H
0.0
2335
|
| Sanofi (ADR) |
|
98,934.5
|
41.3
|
L
 -0.7%
H
41.3
42.1
|
L
 -6.2%
H
40.9
43.6
|
L
 -6.7%
H
40.9
45.2
|
L
 -7.7%
H
40.9
48.6
|
L
 -14.2%
H
40.9
52.7
|
L
 -22.5%
H
40.9
60.1
|
L
 -20.6%
H
36.9
60.1
|
L
 0.3%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
226.5
|
4.0
|
L
 0.8%
H
4.0
4.1
|
L
 5.8%
H
3.8
4.2
|
L
 -18.1%
H
3.6
5
|
L
 -21.9%
H
3.6
5.7
|
L
 39.9%
H
2.8
7.8
|
L
 59.9%
H
1.0
10.5
|
L
 -60.3%
H
1.0
11.0
|
L
 -98.1%
H
1.0
458
|
| Tarsus Pharma Inc |
|
2,887.3
|
67.1
|
L
 1.4%
H
66.4
69.5
|
L
 10.4%
H
60.5
69.5
|
L
 7.8%
H
56
69.5
|
L
 4.7%
H
56
74.4
|
L
 65.3%
H
38.5
85.3
|
L
 267.7%
H
12.7
85.3
|
L
 121.3%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
890.3
|
17.3
|
L
 1.8%
H
17.1
17.7
|
L
 3.5%
H
16.4
17.7
|
L
 5.5%
H
15.5
17.7
|
L
 17.1%
H
14.6
17.7
|
L
 63.4%
H
10.5
21.0
|
L
 61.1%
H
7.4
21.0
|
L
 3.7%
H
6.1
21.0
|
L
 -25.1%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
343.0
|
12.9
|
L
 -5.2%
H
12.9
13.9
|
L
 14.1%
H
11.3
13.9
|
L
 6.6%
H
10.3
13.9
|
L
 -9.4%
H
10.3
17.0
|
L
 130.1%
H
5.6
18.4
|
L
 -47.7%
H
2.8
61.2
|
L
 -99.6%
H
2.8
3625.9
|
L
 -100.0%
H
2.8
88640
|
| TG Therapeutics Inc |
|
8,205.3
|
53.6
|
L
 -0.6%
H
53.1
55.0
|
L
 6.1%
H
50.6
57.4
|
L
 37.9%
H
36.5
57.4
|
L
 76.0%
H
29.7
57.4
|
L
 46.6%
H
25.3
57.4
|
L
 127.1%
H
6.5
57.4
|
L
 41.4%
H
3.5
57.4
|
L
 697.6%
H
3.3
57.4
|
| Alpha Teknova Inc |
|
278.8
|
5.2
|
L
 6.3%
H
4.9
5.3
|
L
 12.8%
H
4.6
5.4
|
L
 33.7%
H
3.9
5.8
|
L
 78.1%
H
2.6
5.8
|
L
 -1.5%
H
1.9
6.7
|
L
 72.8%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
142.5
|
1.1
|
L
 -3.5%
H
1.1
1.2
|
L
 1.8%
H
1.1
1.2
|
L
 -24.3%
H
1.0
1.6
|
L
 -17.0%
H
1.0
1.9
|
L
 -27.7%
H
1.0
2.6
|
L
 55.6%
H
0.4
2.6
|
L
 -53.5%
H
0.4
2.8
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
192.9
|
12.1
|
L
 1.2%
H
11.8
12.3
|
L
 4.0%
H
11.5
12.9
|
L
 -5.3%
H
10.0
13.6
|
L
 -24.8%
H
10.0
16.4
|
L
 -63.1%
H
10.0
70.0
|
L
 -99.8%
H
0.2
6016
|
L
 -100.0%
H
0.2
825600
|
L
 -100.0%
H
0.2
1792000000
|
| Tenaya Therapeutics Inc |
|
158.4
|
0.7
|
L
H
0.7
0.8
|
L
 7.4%
H
0.7
0.8
|
L
 -5.2%
H
0.7
1.0
|
L
 -2.7%
H
0.6
1.2
|
L
 30.4%
H
0.5
2.4
|
L
 -87.3%
H
0.4
7.0
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
17.2
|
1.2
|
L
 -7.9%
H
1.2
1.3
|
L
 -7.2%
H
1.2
1.3
|
L
 -37.6%
H
1.2
1.9
|
L
 -37.0%
H
1.2
2.5
|
L
 -83.1%
H
1.2
12.2
|
L
 -3.3%
H
0.2
12.2
|
L
 -93.2%
H
0.2
41
|
L
 -99.9%
H
0.2
2020.5
|
| Travere Therapeutics Inc |
|
5,364.8
|
57.7
|
L
 3.1%
H
56.0
57.9
|
L
 8.1%
H
53.1
57.9
|
L
 29.8%
H
42.4
57.9
|
L
 107.9%
H
26.5
57.9
|
L
 298.1%
H
14.4
57.9
|
L
 257.4%
H
5.1
57.9
|
L
 288.0%
H
5.1
57.9
|
L
 212.0%
H
5.1
57.9
|
| TherapeuticsMD Inc |
|
23.3
|
2.0
|
L
 0.5%
H
2.0
2.0
|
L
 -12.2%
H
1.9
2.3
|
L
 -5.2%
H
1.8
2.4
|
L
 -13.0%
H
1.8
2.4
|
L
 81.1%
H
1.0
3.0
|
L
 -50.5%
H
0.7
4.4
|
L
 -96.7%
H
0.7
64.5
|
L
 -99.5%
H
0.7
441.5
|
| Universe Pharma INC |
|
1.9
|
3.0
|
L
 -3.0%
H
2.7
3
|
L
 2.1%
H
2.7
3.0
|
L
 2.4%
H
2.6
3.7
|
L
 27.2%
H
2.1
3.7
|
L
 -21.8%
H
2
11
|
L
 -57.2%
H
0.1
64.8
|
L
 -93.5%
H
0.1
75
|
L
H
0.1
179.9
|
| United Therapeutics Corp |
|
23,341.5
|
549.9
|
L
 1.0%
H
544.1
555
|
L
 0.3%
H
532.6
555.9
|
L
 -3.3%
H
532.6
580.4
|
L
 5.5%
H
517.6
609.4
|
L
 92.0%
H
272.1
609.4
|
L
 147.3%
H
208.6
609.4
|
L
 214.9%
H
158.4
609.4
|
L
 422.3%
H
74.3
609.4
|
| Vericel Corp |
|
2,129.0
|
41.7
|
L
 3.2%
H
40.6
42.1
|
L
 8.4%
H
38.2
42.1
|
L
 20.0%
H
32.0
42.1
|
L
 28.5%
H
29.0
42.1
|
L
 -0.3%
H
29.0
43.6
|
L
 14.3%
H
29.0
63
|
L
 -35.7%
H
17.3
68.9
|
L
 1720.5%
H
2.0
68.9
|
| Veru Inc |
|
47.7
|
3.0
|
L
 -2.3%
H
2.9
3.1
|
L
 -5.1%
H
2.8
3.1
|
L
 26.4%
H
2.1
7.3
|
L
 29.1%
H
2.1
7.3
|
L
 -52.1%
H
2.1
7.3
|
L
 -73.7%
H
2.1
19.2
|
L
 -96.5%
H
2.1
245.5
|
L
 -77.7%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
50.8
|
1.5
|
L
 -2.6%
H
1.5
1.6
|
L
 0.7%
H
1.4
1.6
|
L
 -15.6%
H
1.4
1.8
|
L
 -45.7%
H
1.3
2.9
|
L
 -68.3%
H
1.3
9.5
|
L
 10.2%
H
0.1
29.3
|
L
 -78.3%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
4,396.9
|
37.9
|
L
 8.8%
H
35.0
38.1
|
L
 27.7%
H
29.6
38.1
|
L
 22.6%
H
27.2
38.1
|
L
 16.3%
H
27.2
38.1
|
L
 52.3%
H
23.0
43.2
|
L
 85.6%
H
8.3
99.4
|
L
 519.8%
H
2.0
99.4
|
L
 2978.9%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
354.8
|
5.9
|
L
 -0.8%
H
5.9
6.1
|
L
 3.0%
H
5.7
6.1
|
L
 -4.7%
H
5.6
6.7
|
L
 -15.7%
H
5.6
7.8
|
L
 32.0%
H
4.1
9.9
|
L
 -9.5%
H
3.3
9.9
|
L
 -68.8%
H
3.3
21.9
|
L
 -48.0%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
100.5
|
5.9
|
L
 3.5%
H
5.7
6.1
|
L
 -2.5%
H
5.3
6.2
|
L
 -3.5%
H
5.3
6.8
|
L
 20.6%
H
4.2
8.5
|
L
 891.5%
H
0.5
9.8
|
L
 -2.3%
H
0.4
11.4
|
L
 -50.3%
H
0.4
14.8
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
1,912.6
|
17.3
|
L
 0.2%
H
17.2
17.8
|
L
 8.4%
H
16.1
18.2
|
L
 0.5%
H
15.5
18.2
|
L
 -37.3%
H
13.2
28.6
|
L
 17.7%
H
13.2
34.3
|
L
 -32.7%
H
9.9
34.3
|
L
 -0.3%
H
9.5
39
|
L
 -83.9%
H
4.7
270
|
| Vertex Pharma |
|
120,608.3
|
475.2
|
L
 1.5%
H
469.9
480.9
|
L
 4.9%
H
447.5
480.9
|
L
 9.4%
H
420.0
480.9
|
L
 5.3%
H
412.3
480.9
|
L
 7.1%
H
362.5
507.9
|
L
 36.9%
H
335.8
519.9
|
L
 153.4%
H
176.4
519.9
|
L
 438.8%
H
71.5
519.9
|
| Viatris |
|
18,551.3
|
15.9
|
L
 1.1%
H
15.8
16.1
|
L
 -0.7%
H
14.9
16.2
|
L
 -4.3%
H
14.9
16.8
|
L
 19.9%
H
12.9
17.5
|
L
 80%
H
8.6
17.5
|
L
 63.2%
H
6.9
17.5
|
L
 12.4%
H
6.9
17.5
|
L
 -65.5%
H
6.9
50.4
|
| vTv Therapeutics Inc (Class A) |
|
140.8
|
35.7
|
L
 1.2%
H
34.5
36.0
|
L
 10.9%
H
31.9
36.0
|
L
 3.9%
H
30.4
37.4
|
L
 -4.1%
H
28.8
43.1
|
L
 135.4%
H
14
44
|
L
 4541.6%
H
0.4
44
|
L
 1323.9%
H
0.4
44
|
L
 481.1%
H
0.4
44
|
| VYNE Therapeutics Inc |
|
21.7
|
0.7
|
L
H
0.7
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 -3.0%
H
0.6
0.7
|
L
 4.8%
H
0.6
0.7
|
L
 -28.6%
H
0.3
2.0
|
L
 -86.5%
H
0.3
6.8
|
L
 -99.0%
H
0.3
68.8
|
L
H
0.3
2869.9
|
| Vaccitech PLC (ADR) |
|
25.4
|
0.7
|
L
 -1.5%
H
0.7
0.7
|
L
 -5.7%
H
0.7
0.8
|
L
 -4.4%
H
0.6
0.8
|
L
 8.2%
H
0.5
0.8
|
L
 -25.8%
H
0.5
2.9
|
L
 -71.1%
H
0.5
5.1
|
L
 -95.9%
H
0.5
18.0
|
L
H
0.5
18.0
|
| Xenetic Biosciences Inc |
|
6.6
|
2.9
|
L
H
2.9
3.0
|
L
 -5.2%
H
2.8
3.1
|
L
 -4.3%
H
2.8
3.5
|
L
 -7.4%
H
2.7
3.7
|
L
 5.8%
H
1.9
13.9
|
L
 -8.8%
H
1.9
13.9
|
L
 -86.4%
H
1.9
56.8
|
L
 -99.5%
H
1.9
1074
|
| Xenon Pharma Inc |
|
5,372.7
|
55.6
|
L
 1.8%
H
54.6
56.6
|
L
 6.9%
H
52.1
56.6
|
L
 2.6%
H
50.9
56.6
|
L
 2.1%
H
50.9
60.0
|
L
 76.5%
H
30
64.0
|
L
 38.9%
H
26.7
64.0
|
L
 208.8%
H
14.7
64.0
|
L
 790.7%
H
2.1
64.0
|
| Xilio Therapeutics Inc |
|
59.2
|
9.0
|
L
 1.2%
H
8.9
9.1
|
L
 9.2%
H
7.8
9.3
|
L
 9.2%
H
7.5
9.3
|
L
 14.6%
H
7.4
9.3
|
L
 -3.9%
H
6.5
12.7
|
L
 -76.5%
H
6.5
41.1
|
L
H
6.5
391.3
|
L
H
6.5
391.3
|
| XOMA Corp |
|
745.2
|
42.2
|
L
 0.5%
H
41.8
42.2
|
L
 0.9%
H
40.8
42.2
|
L
 1.2%
H
40.8
42.4
|
L
 41.6%
H
28.6
42.8
|
L
 60.8%
H
22.3
42.8
|
L
 127.7%
H
13.5
42.8
|
L
 31.8%
H
13.5
42.8
|
L
 271.7%
H
4.0
46.3
|
| XORTX Therapeutics Inc |
|
3.7
|
2.1
|
L
 1.4%
H
2.1
2.2
|
L
 -3.2%
H
2
2.3
|
L
 -3.2%
H
2
2.7
|
L
 -79.2%
H
1.7
10.5
|
L
 -90.1%
H
1.7
35.3
|
L
 -98.6%
H
1.7
188.1
|
L
 -99.3%
H
1.7
1841.6
|
L
H
1.7
1841.6
|
| Zevra Therapeutics Inc |
|
773.2
|
13.1
|
L
 0.6%
H
12.9
13.3
|
L
 3.4%
H
12.5
13.3
|
L
 30.4%
H
10.1
14.3
|
L
 38.9%
H
8.7
14.3
|
L
 45.3%
H
7.2
14.3
|
L
 136.5%
H
3.9
14.3
|
L
 -8.5%
H
3.9
14.5
|
L
 -81.4%
H
1.9
134.4
|
| Zymeworks BC Inc |
|
1,787.8
|
24.3
|
L
 1.8%
H
24.1
24.5
|
L
 8.1%
H
22.6
24.5
|
L
 -5.1%
H
22.1
26.2
|
L
 1.2%
H
22.1
29.8
|
L
 94.9%
H
11.5
29.8
|
L
 199.6%
H
6.0
29.8
|
L
 -33.2%
H
4.1
39.4
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
427.9
|
6.9
|
L
 -1.8%
H
6.8
7.2
|
L
 10%
H
6.3
7.3
|
L
 -2.3%
H
6.2
7.6
|
L
 42.0%
H
4.5
9.4
|
L
 -17.1%
H
4.5
11.4
|
L
 -9.1%
H
1.7
20.7
|
L
 -9.1%
H
1.7
20.7
|
L
 -9.1%
H
1.7
20.7
|
| CervoMed Inc |
|
30.2
|
3.3
|
L
 -12.4%
H
3.0
3.7
|
L
 -27.9%
H
3.0
7.8
|
L
 6.5%
H
2.1
7.8
|
L
 -18.9%
H
2.1
7.8
|
L
 -50%
H
2.1
13.1
|
L
 -38.5%
H
1.8
26.4
|
L
 -94.7%
H
1.8
64.1
|
L
 -100.0%
H
1.8
17437.5
|
| Dianthus Therapeutics Inc |
|
4,963.7
|
90.8
|
L
 3.7%
H
88.0
92.8
|
L
 15.1%
H
78.7
92.8
|
L
 5%
H
68.9
93.6
|
L
 14.5%
H
68.9
96.5
|
L
 427.9%
H
17.1
96.5
|
L
 11847.4%
H
6.6
96.5
|
L
 11847.4%
H
6.6
96.5
|
L
 11847.4%
H
6.6
96.5
|
| Neumora Therapeutics Inc |
|
270.5
|
1.5
|
L
 -9.3%
H
1.4
1.6
|
L
 -6.4%
H
1.3
1.7
|
L
 -21.1%
H
0.8
2.0
|
L
 -40.9%
H
0.8
2.6
|
L
 94.7%
H
0.7
3.7
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Agape ATP Corp |
|
3.2
|
3.2
|
L
 -2.2%
H
3.0
3.3
|
L
 11.3%
H
2.6
6.1
|
L
 13.3%
H
2.6
8.5
|
L
 51.4%
H
2.0
8.5
|
L
 -95.4%
H
1.7
75.3
|
L
 -99.8%
H
1.7
1590
|
L
 -99.8%
H
1.7
1590
|
L
 -99.8%
H
1.7
1590
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
27.0
|
0.7
|
L
 -1.5%
H
0.7
0.7
|
L
 -5.7%
H
0.7
0.8
|
L
 -4.4%
H
0.6
0.8
|
L
 8.2%
H
0.5
0.8
|
L
 -25.8%
H
0.5
2.9
|
L
 -81.9%
H
0.5
5.1
|
L
 -81.9%
H
0.5
5.1
|
L
 -81.9%
H
0.5
5.1
|
| Viamet Pharma Corp |
|
1,211.9
|
11.2
|
L
 -3.9%
H
10.9
11.4
|
L
 -13.4%
H
10.9
13.3
|
L
 -6.1%
H
10.7
13.8
|
L
 9.2%
H
9.1
13.8
|
L
 6.4%
H
9.1
13.8
|
L
 6.4%
H
9.1
13.8
|
L
 6.4%
H
9.1
13.8
|
L
 6.4%
H
9.1
13.8
|
| Onconetix Inc |
|
3.7
|
1
|
L
 -6.5%
H
1.0
1.1
|
L
 -7.4%
H
0.9
1.1
|
L
 -19.4%
H
0.9
1.4
|
L
 -96.7%
H
0.9
67.3
|
L
 -99.5%
H
0.9
270
|
L
 -100.0%
H
0.9
222700
|
L
 -100.0%
H
0.9
15453000
|
L
 -100.0%
H
0.9
15453000
|
| Talphera Inc |
|
55.0
|
1.1
|
L
 1.0%
H
1.1
1.1
|
L
 15.2%
H
0.9
1.1
|
L
 29.3%
H
0.8
1.1
|
L
 32.5%
H
0.7
1.1
|
L
 140.9%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| ArriVent BioPharma Inc |
|
1,491.3
|
32.0
|
L
 -5.1%
H
32.0
34.3
|
L
 5.6%
H
30.3
34.7
|
L
 19.8%
H
26.6
34.7
|
L
 44.4%
H
20.7
34.7
|
L
 40.4%
H
16.1
34.7
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
| Skye Bioscience Inc |
|
23.9
|
0.7
|
L
 -2.9%
H
0.7
0.7
|
L
 -5.6%
H
0.7
0.8
|
L
 -18.1%
H
0.7
0.9
|
L
 6.3%
H
0.6
1.1
|
L
 -76.3%
H
0.6
5.8
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
| Actuate Therapeutics Inc |
|
46.7
|
2.0
|
L
 1.0%
H
1.9
2.1
|
L
 -3.9%
H
1.9
2.3
|
L
 -18.1%
H
1.8
2.8
|
L
 -20.1%
H
1.6
3.4
|
L
 -72.3%
H
1.6
9.2
|
L
H
1.6
12.0
|
L
H
1.6
12.0
|
L
H
1.6
12.0
|
| Bicara Therapeutics Inc |
|
1,684.6
|
25.6
|
L
 2.6%
H
24.2
26.3
|
L
 16.8%
H
21.9
26.3
|
L
 18.3%
H
19.1
26.3
|
L
 39.4%
H
17.6
26.3
|
L
 179.3%
H
8.5
26.3
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
| Gelteq Ltd |
|
7.4
|
0.7
|
L
 -5.5%
H
0.7
0.7
|
L
 -43.9%
H
0.7
1.4
|
L
 64.3%
H
0.4
2.0
|
L
 -2.8%
H
0.4
2.0
|
L
 -56.1%
H
0.4
2.0
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
L
H
0.4
5.5
|
| Septerna Inc |
|
1,625.0
|
36.1
|
L
 -1.4%
H
35.6
38.0
|
L
 2.5%
H
33.9
38.0
|
L
 27.1%
H
27.1
38.0
|
L
 51.6%
H
22.8
38.0
|
L
 242.4%
H
10.3
38.0
|
L
H
4.2
38.0
|
L
H
4.2
38.0
|
L
H
4.2
38.0
|
| Alpha Cognition Inc |
|
143.3
|
6.6
|
L
H
6.4
6.8
|
L
 9.5%
H
6.0
7.0
|
L
 12.5%
H
5.6
7.0
|
L
 13.5%
H
4.9
7.6
|
L
 -26.9%
H
4.5
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
| Atlantic Intl Corp |
|
59.5
|
0.8
|
L
 -41.4%
H
0.7
1.5
|
L
 47.2%
H
0.4
1.8
|
L
 -45.1%
H
0.4
1.8
|
L
 -79.0%
H
0.4
3.7
|
L
 -70.8%
H
0.4
5.3
|
L
 -70%
H
0.4
5.3
|
L
 -70%
H
0.4
5.3
|
L
 -70%
H
0.4
5.3
|
| BeiGene Ltd (ADR) |
|
28,751.5
|
277.1
|
L
 0.4%
H
275.8
282.9
|
L
 5%
H
259.1
282.9
|
L
 -10.7%
H
254.0
312.0
|
L
 0.9%
H
254.0
328.4
|
L
 7.6%
H
239.3
385.2
|
L
 50.0%
H
172.7
385.2
|
L
 50.0%
H
172.7
385.2
|
L
 50.0%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
12.1
|
0.3
|
L
 4.2%
H
0.2
0.3
|
L
 4.2%
H
0.2
0.3
|
L
 4.2%
H
0.2
0.3
|
L
 -37.5%
H
0.2
0.5
|
L
 -79.2%
H
0.2
3.3
|
L
 -56.9%
H
0.2
3.3
|
L
 -56.9%
H
0.2
3.3
|
L
 -56.9%
H
0.2
3.3
|
| Ascentage Pharma Grp Intl (ADR) |
|
1,594.2
|
17.1
|
L
 0.4%
H
17.0
17.1
|
L
 0.4%
H
17.0
18.1
|
L
 -18.7%
H
16.9
20.9
|
L
 -23.5%
H
16.9
28.1
|
L
 -54.0%
H
16.9
48.5
|
L
 -1.7%
H
16.9
48.5
|
L
 -1.7%
H
16.9
48.5
|
L
 -1.7%
H
16.9
48.5
|
| Maze Therapeutics Inc |
|
1,476.1
|
26.7
|
L
 1.0%
H
26.3
27
|
L
 11.8%
H
23.9
27
|
L
 3.5%
H
22.7
27
|
L
 -45.6%
H
22.7
49.3
|
L
 148.6%
H
9.8
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
| Aardvark Therapeutics Inc |
|
108.2
|
5.0
|
L
 17.3%
H
4.2
5.2
|
L
 33.3%
H
3.6
5.2
|
L
 9.3%
H
3.4
5.2
|
L
 22.2%
H
3.4
6.8
|
L
 -62.8%
H
3.4
17.9
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
L
H
3.4
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
15.4
|
5.7
|
L
 45.7%
H
5.1
7.4
|
L
 8.9%
H
3.7
7.4
|
L
 165.7%
H
1.9
14.8
|
L
 114.2%
H
1.8
14.8
|
L
 -87.7%
H
1.8
76
|
L
H
1.8
76
|
L
H
1.8
76
|
L
H
1.8
76
|
| Jyong Biotech Ltd |
|
129.2
|
1.7
|
L
 6.1%
H
1.6
1.8
|
L
 8.8%
H
1.5
1.8
|
L
 -19.1%
H
1.5
2.3
|
L
 -10.8%
H
1.5
3
|
L
 -76.9%
H
1.4
67
|
L
 -82.8%
H
1.4
67
|
L
 -82.8%
H
1.4
67
|
L
 -82.8%
H
1.4
67
|
| Black Titan Corp |
|
8.6
|
0.8
|
L
H
0.7
0.8
|
L
 15.9%
H
0.7
0.9
|
L
 -27.3%
H
0.7
1.2
|
L
 -38.0%
H
0.7
1.8
|
L
 -96.7%
H
0.7
23.5
|
L
 -96.7%
H
0.7
23.5
|
L
 -96.7%
H
0.7
23.5
|
L
 -96.7%
H
0.7
23.5
|
| MapLight Therapeutics Inc |
|
1,389.8
|
30.7
|
L
 7.0%
H
28.2
30.7
|
L
 12.9%
H
27.2
31.5
|
L
 6.6%
H
25.7
31.5
|
L
 79.5%
H
16.3
33.3
|
L
 67.1%
H
12.2
33.3
|
L
 67.1%
H
12.2
33.3
|
L
 67.1%
H
12.2
33.3
|
L
 67.1%
H
12.2
33.3
|
| NovaBridge Biosciences ADR |
|
185.0
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 6.0%
H
1.5
1.7
|
L
 -9.6%
H
1.5
1.9
|
L
 -39.2%
H
1.5
2.8
|
L
 -64.8%
H
1.5
5.2
|
L
 -64.8%
H
1.5
5.2
|
L
 -64.8%
H
1.5
5.2
|
L
 -64.8%
H
1.5
5.2
|
| Evommune Inc |
|
848.6
|
23.6
|
L
 -2.9%
H
23.3
25.5
|
L
 17.5%
H
19.7
25.5
|
L
 3.0%
H
19.3
25.5
|
L
 0.5%
H
19.3
29.1
|
L
 16.5%
H
13.9
33.2
|
L
 16.5%
H
13.9
33.2
|
L
 16.5%
H
13.9
33.2
|
L
 16.5%
H
13.9
33.2
|
| Aktis Oncology Inc |
|
-
|
28.7
|
L
 6.3%
H
26.2
28.9
|
L
 26.8%
H
23.0
28.9
|
L
 41.1%
H
18.3
28.9
|
L
 57.9%
H
14.7
28.9
|
L
 28.1%
H
14.7
28.9
|
L
 28.1%
H
14.7
28.9
|
L
 28.1%
H
14.7
28.9
|
L
 28.1%
H
14.7
28.9
|
| Helus Pharma Inc |
|
254.0
|
5.1
|
L
 5.0%
H
5.0
5.4
|
L
 18.7%
H
4.2
5.4
|
L
 8.8%
H
3.8
5.4
|
L
 12.1%
H
3.8
6.3
|
L
 -32.4%
H
3.8
8.6
|
L
 -32.4%
H
3.8
8.6
|
L
 -32.4%
H
3.8
8.6
|
L
 -32.4%
H
3.8
8.6
|
| NervGen Pharma Corp |
|
211.3
|
2.0
|
L
 -3.4%
H
2.0
2.2
|
L
 -0.5%
H
1.9
2.3
|
L
 -4.3%
H
1.7
2.3
|
L
 -49.8%
H
1.7
4.7
|
L
 -65.4%
H
1.7
5.9
|
L
 -65.4%
H
1.7
5.9
|
L
 -65.4%
H
1.7
5.9
|
L
 -65.4%
H
1.7
5.9
|
| Veradermics Inc |
|
4,900.2
|
117.3
|
L
 13.2%
H
102.9
118.7
|
L
 29.0%
H
86.8
118.7
|
L
 15.4%
H
86.8
118.7
|
L
 89.4%
H
53.7
118.7
|
L
 210.7%
H
35.1
118.7
|
L
 210.7%
H
35.1
118.7
|
L
 210.7%
H
35.1
118.7
|
L
 210.7%
H
35.1
118.7
|
| Eikon Therapeutics Inc |
|
521.4
|
9.6
|
L
 1.3%
H
9.4
10.1
|
L
 6.2%
H
9
10.3
|
L
 -11.7%
H
8.0
11.4
|
L
 -17.8%
H
7.9
13.5
|
L
 -35.8%
H
7.9
16.5
|
L
 -35.8%
H
7.9
16.5
|
L
 -35.8%
H
7.9
16.5
|
L
 -35.8%
H
7.9
16.5
|
| Satellos Bioscience Inc |
|
117.1
|
5.6
|
L
 -0.9%
H
5.4
5.6
|
L
 -2.3%
H
5.4
6.0
|
L
 -16.7%
H
5.4
7.5
|
L
 -23.3%
H
5.4
9.5
|
L
 -50.0%
H
5.4
13.4
|
L
 -50.0%
H
5.4
13.4
|
L
 -50.0%
H
5.4
13.4
|
L
 -50.0%
H
5.4
13.4
|
| Avalyn Pharma Inc |
|
1,334.0
|
30.1
|
L
 -6.8%
H
29.8
33.2
|
L
 7.2%
H
28
33.2
|
L
 4.3%
H
24.2
33.2
|
L
 2.0%
H
24.2
33.2
|
L
 2.0%
H
24.2
33.2
|
L
 2.0%
H
24.2
33.2
|
L
 2.0%
H
24.2
33.2
|
L
 2.0%
H
24.2
33.2
|
| Seaport Therapeutics Inc |
|
1,033.7
|
19.3
|
L
 1.8%
H
18.7
20.0
|
L
 7.5%
H
16.8
20.0
|
L
 10.3%
H
16
20.0
|
L
 -2.7%
H
14.9
20.0
|
L
 -2.7%
H
14.9
20.0
|
L
 -2.7%
H
14.9
20.0
|
L
 -2.7%
H
14.9
20.0
|
L
 -2.7%
H
14.9
20.0
|
| Palatin Technologies Inc |
|
-
|
10.6
|
L
 -5.4%
H
10.0
11.0
|
L
 -10.7%
H
10.0
12.3
|
L
 -25.1%
H
10.0
14.8
|
L
 -25.1%
H
10.0
14.8
|
L
 -25.1%
H
10.0
14.8
|
L
 -25.1%
H
10.0
14.8
|
L
 -25.1%
H
10.0
14.8
|
L
 -25.1%
H
10.0
14.8
|